• If you are citizen of an European Union member nation, you may not use this service unless you are at least 16 years old.

  • Finally, you can manage your Google Docs, uploads, and email attachments (plus Dropbox and Slack files) in one convenient place. Claim a free account, and in less than 2 minutes, Dokkio (from the makers of PBworks) can automatically organize your content for you.


Pathogenesis of Type 2 Diabetes Mellitus

Page history last edited by Robert Rushakoff, MD 12 years, 7 months ago


Ralph A DeFronzo, MD,

Lawrence J Mandarino, PhD 






In the postabsorptive state (10-12 hour overnight fast), the majority of total body glucose disposal takes place in insulin dependent tissues (1). Under basal conditions approximately 50% of all glucose utilization occurs in the brain, which is insulin independent and becomes saturated at a plasma glucose concentration of about 40 mg/dl (2). Another 25% of glucose uptake occurs in the splanchnic area (liver plus gastrointestinal tissues) and also is insulin independent (3). The remaining 25% of glucose metabolism in the postabsorptive state takes place in insulin-dependent tissues, primarily muscle (4,5). Basal glucose utilization averages ~2.0 mg/kgomin and is precisely matched by the rate of endogenous glucose production (1,3-7) . Approximately 85% of endogenous glucose production is derived from the liver, and the remaining amount is produced by the kidney (1,8,9). Approximately half of basal hepatic glucose production is derived from glycogenolysis and half from gluconeogenesis (9,10).


Following glucose ingestion, the balance between endogenous glucose production and tissue glucose uptake is disrupted. The increase in plasma glucose concentration stimulates insulin release from the pancreatic beta cells, and the resultant hyperinsulinemia and hyperglycemia serve (i) to stimulate glucose uptake by splanchnic (liver and gut) and peripheral (primarily muscle) tissues (Table 1) and (ii) to suppress endogenous glucose production (1,3-7,11-14). Hyperglycemia, in the absence of hyperinsulinemia, exerts its own independent effect to stimulate muscle glucose uptake and to suppress endogenous glucose production in a dose dependent fashion (14-16). The majority (~80-85%) of glucose that is taken up by peripheral tissues is disposed of in muscle (1,3-7,11-14), with only a small amount (~4-5%) being metabolized by adipocytes (17). Although fat tissue is responsible for only a small amount of total body glucose disposal, it plays a very important role in the maintenance of total body glucose homeostasis (see below). Insulin is a potent inhibitor of lipolysis and even small increments in the plasma insulin concentration exert a potent antilipolytic effect, leading to a marked reduction in the plasma free fatty acid level (18). The decline in plasma FFA concentration results in increased glucose uptake in muscle (19) and contributes to the inhibition of hepatic glucose production (16,20). Thus, changes in the plasma FFA concentration in response to increased plasma levels of insulin and glucose play an important role in the maintenance of normal glucose homeostasis (21,22).








The maintenance of whole-body glucose homeostasis is dependent upon a normal insulin secretory response by the pancreatic beta cells and normal tissue sensitivity to the independent effects of hyperinsulinemia and hyperglycemia (i.e., the mass-action effect of glucose) to augment glucose uptake. In turn, the combined effects of insulin and hyperglycemia to promote glucose disposal are dependent on three tightly coupled mechanisms (Table 1): (i) suppression of endogenous (primarily hepatic) glucose production; (ii) stimulation of glucose uptake by the splanchnic (hepatic plus gastrointestinal) tissues; and (iii) stimulation of glucose uptake by peripheral tissues, primarily muscle (1,4,14). Muscle glucose uptake is regulated by flux through two major metabolic pathways: glycolysis (of which ~90% represents glucose oxidation) and glycogen synthesis.


Hepatic Glucose Production

In the overnight fasted state the liver of healthy subjects produces glucose at the rate of ~1.8-2.0 mgokg-1omin-1 (1,3,4,6,18,54). This glucose flux is essential to meet the needs of the brain and other neural tissues, which utilize glucose at a constant rate of ~1-1.2 mgokg-1omin-1 (2,169). Brain glucose uptake accounts for ~50-60% of glucose disposal during the postabsorptive state and this uptake is insulin independent. Therefore, brain glucose uptake occurs at the same rate during absorptive and postabsorptive periods and is not altered in type 2 diabetes (214). Following glucose ingestion, insulin is secreted into the portal vein and carried to the liver, where it suppresses hepatic glucose output. If the liver does not perceive this insulin signal and continues to produce glucose, there will be two inputs of glucose into the body, one from the liver and another from the gastrointestinal tract, and marked hyperglycemia will ensue.


In type 2 diabetic subjects with mild to moderate fasting hyperglycemia (140-200 mg/dl, 7.8-11.1 mmol/L), basal hepatic glucose production is increased by ~0.5 mg/kgomin . Consequently, during the overnight sleeping hours (2200 h to 0800 h), the liver of a 80-kg diabetic individual with modest fasting hyperglycemia adds an additional 35 g of glucose to the systemic circulation. The increase in basal HGP is closely correlated with the severity of fasting hyperglycemia (1,3,4,6,18,54,157-159,162) . Thus, in type 2 diabetics with overt fasting hyperglycemia (>140 mg/dl, 7.8 mmol/l), an excessive rate of hepatic glucose output is the major abnormality responsible for the elevated fasting plasma glucose concentration. The close relationship between fasting plasma glucose concentration and HGP has been demonstrated in numerous studies (164-166,170-174).

In the postabsorptive state, the fasting plasma insulin concentration in type 2 diabetics is 2-4 fold greater than in nondiabetic subjects. Because hyperinsulinemia is a potent inhibitor of HGP (1,3,4-6,16,18,164,165,175), hepatic resistance to the action of insulin must be present in the postabsorptive state to explain the excessive output of glucose by the liver. Hyperglycemia per se also exerts a powerful suppressive action on HGP (15,167,175-177). Therefore, the liver also must be glucose resistance with respect to the inhibitory effect of hyperglycemia to suppress hepatic glucose output, and this has been well documented (15,167,178,179).


Using the euglycemic insulin clamp technique in combination with tritiated glucose, the dose response relationship between hepatic glucose production and the plasma glucose concentration has been defined by Groop, DeFronzo, et al (18) . The following points should be emphasized: (i) first, the dose-response curve relating inhibition of HGP to the plasma insulin concentration is quite steep, with an effective dose for half-maximal insulin concentration (ED50) of ~30-40 µU/ml; (ii) second, in type 2 diabetic individuals the dose response curve is shifted to the right, indicating the presence of hepatic resistance to the inhibitory effect of insulin on hepatic glucose production. However, at plasma insulin concentrations within the high physiologic range (~100 uU/ml), the hepatic insulin resistance can be largely overcome and a near normal suppression of HGP can be achieved; (iii) third, the severity of the hepatic insulin resistance is related to the severity of the diabetic state. In type 2 diabetic individuals with mild fasting hyperglycemia, an increment in plasma insulin concentration of 100 µU/ml causes a complete suppression of HPG. However, in diabetic subjects with more severe fasting hyperglycemia, the ability of the same plasma insulin concentration to suppress HGP is impaired (18). These results suggest that there is an acquired component of hepatic insulin resistance and that this defect becomes progressively worse as the diabetic state decompensates over time.


The glucose released by the liver can be derived from either glycogenolysis or gluconeogenesis (6,16,176). Studies employing the hepatic vein catheter technique have shown that the uptake of gluconeogenic precursors, especially lactate, is increased in type 2 diabetic subjects (180). Consistent with this observation, radioisotope turnover studies, using lactate, alanine, and glycerol, have shown that ~90% of the increase in HGP above baseline can be accounted for by accelerated gluconeogenesis (181,182). More recent studies employing 13C-magnetic resonance imaging (183) and D2O (184,185) have confirmed the important contribution of accelerated gluconeogenesis to the increase in HGP. An increased rate of glutamine conversion to glucose also has been shown to contribute to the elevated rate of gluconeogenesis in type 2 diabetic subjects (186). The mechanisms responsible for the increase in hepatic gluconeogenesis include hyperglucagonemia (187), increased circulating levels of gluconeogenic precursors (lactate, alanine, glycerol) (181,188), increased FFA oxidation (18,162,189), enhanced sensitivity to glucagon (190) and decreased sensitivity to insulin (1,4.18,164,165). Although the majority of evidence indicates that increased gluconeogenesis is the major cause of the increase in HGP in type 2 diabetic subjects (181-186), it is likely that accelerated glycogenolysis also contributes (181,191).


Because of the inaccessibility of the liver in man, it has been difficult to assess the role of key enzymes involved in the regulation of gluconeogenesis (pyruvate carboxylase, phosphoenol- pyruvate carboxykinase), glycogenolysis (glycogen phosphorylase), and net hepatic glucose output (glucokinase, glucose-6-phosphatase). However, considerable evidence from animal models of type 2 diabetes and some evidence in humans have implicated increased activity of PEPCK and G-6-Pase in the accelerated rate of hepatic glucose production (192-194).


The kidney also has been shown to produce glucose and estimates of the renal contribution to total endogenous glucose production have varied from 5% to 20% (8,9,195). These varying estimates of the contribution of renal gluconeogenesis to total glucose production are largely related to the methodology employed to measure glucose production by the kidney (196). One unconfirmed study suggests that the rate of renal gluconeogenesis is increased in type 2 diabetics with fasting hyperglycemia (197). Arguing against this possibility are studies employing the hepatic vein catheter technique which have shown that all of the increase in total body endogenous glucose production (measured with 3-3H-glucose) in type 2 diabetics can be accounted for by increased hepatic glucose output (measured by the hepatic vein catheter technique) (3).



Peripheral (Muscle) Glucose Uptake

Muscle is the major site of glucose disposal in man (1,3-5,14). Under euglycemic hyperinsulinemic conditions, approximately 80% of total body glucose uptake occurs in skeletal muscle (1,3-5). Studies employing the euglycemic insulin clamp in combination with femoral artery/vein catheterization have examined the effect of insulin on leg glucose uptake in type 2 diabetic and control subjects (3) . Since bone is metabolically inert and adipose tissue takes up less than 5% of an infused glucose load (17,198,199), muscle represents the major tissue responsible for leg glucose uptake.


In response to a physiologic increase in plasma insulin concentration (~80-100 uU/ml), leg (muscle) glucose uptake increases linearly, reaching a plateau value of 10 mg/kg leg wt per minute (3) . In contrast, in lean type 2 diabetic subjects, the onset of insulin action is delayed for ~40 min and the ability of the hormone to stimulate leg glucose uptake is markedly blunted, even though the study is carried out for an additional 60 min in the type 2 diabetic group to allow insulin to more fully express its biological effects (3). During the last hour of the insulin clamp study, the rate of glucose uptake was reduced by 50% in the diabetic group (3). These results provide conclusive evidence that the primary site of insulin resistance during euglycemic insulin clamp studies performed in type 2 diabetic subjects resides in muscle tissue. Using the forearm and leg catheterization techniques (13,153,200,202), a number of investigators have demonstrated a decreased rate of insulin-mediated glucose uptake by peripheral tissues. The use of positron emission tomography (PET) scanning to quantitate leg glucose uptake in type 2 diabetic subjects has provided additional support for the presence of severe muscle resistance to insulin in diabetic subjects (203).



Splanchnic (Hepatic) Glucose Uptake

In humans, it is difficult to catheterize the portal vein, and glucose disposal by the liver has not been examined directly. Using the hepatic vein catheterization technique in combination with the euglycemic insulin clamp, the contribution of the splanchnic (liver plus gastrointestinal) tissues to overall glucose homeostasis has been examined in lean type 2 diabetic subjects with mild to moderate fasting hyperglycemia (3). In the postabsorptive state, there is a net release of glucose from the splanchnic area (i.e., negative balance) in both control and type 2 diabetic subjects , reflecting glucose production by the liver. In response to insulin, splanchnic glucose output is promptly suppressed (reflecting the inhibition of HGP) and, by 20 min, the net glucose balance across the splanchnic region declines to zero (i.e., there was no net uptake or release) (3). After 2 h of sustained hyperinsulinemia, there is a small net uptake of glucose (~0.5 mgokg-1omin-1) by the splanchnic area (i.e., positive balance). This uptake is virtually identical to the rate of splanchnic glucose uptake observed in the basal state, indicating that the splanchnic tissues, like the brain, are insensitive to insulin at least with respect to the stimulation of glucose uptake (3,5,6,175). There was no difference between diabetic and control subjects in the amount of glucose taken up by the splanchnic tissues at any time during the insulin clamp study (3).


The results of these studies illustrate another important point: namely, that under conditions of euglycemic hyperinsulinemia, very little of the infused glucose is taken up by the splanchnic (and therefore hepatic) tissues (3,5,6,175). During the insulin clamp, the rate of whole body glucose uptake averaged 7 mgokg-1omin-1, and of this, only 0.5 mgokg-1omin-1 or 7%, was disposed of by the splanchnic region. Because the difference in insulin-mediated total body glucose uptake between the type 2 diabetic and control groups during the euglycemic insulin clamp study was 2.5 mgokg-1omin-1, from a purely quantitative standpoint it is obvious that a defect in splanchnic (hepatic) glucose removal never could account for the magnitude of impairment in total body glucose uptake following intravenous glucose/insulin administration. However, after glucose ingestion, the oral route of administration and the resultant hyperglycemia conspire to enhance splanchnic (hepatic) glucose uptake (6,7,11,12,16,26,175) and, under these conditions, diminished hepatic glucose uptake has been shown to contribute to the impairment in glucose tolerance in type 2 diabetes (see discussion below) (6,204,205).



Summary: Whole Body Glucose Utilization

Insulin-mediated whole body glucose utilization during the euglycemic insulin clamp is summarized in Fig. 12 (coming soon). The total height of each bar represents the amount of glucose taken up by all tissues in the body during the insulin clamp in control and type 2 diabetic subjects. Net splanchnic glucose uptake, quantitated by the hepatic venous catheterization technique, is similar in both groups and averaged 0.5 mgokg-1omin-1. Adipose tissue glucose uptake accounts for less than 5% of total glucose disposal (17,198,199). Brain glucose uptake, estimated to be 1.0-1.2 mgokg-1omin-1 in the postabsorptive state (2,169,206), is unaffected by hyperinsulinemia (169). Muscle glucose uptake (extrapolated from leg catheterization data) in control subjects accounts for ~75-80% of the total glucose uptake (1,3,4). In type 2 diabetic subjects, the largest part of the impairment in insulin-mediated glucose uptake is accounted for by a defect in muscle glucose disposal. Even if adipose tissue of type 2 diabetic subjects took up absolutely no glucose, it could, at best, explain only a small fraction of the defect in whole body glucose metabolism.



Glucose Disposal During OGTT

In every day life, the gastrointestinal tract represents the normal route of glucose entry into the body. However, the assessment of tissue glucose disposal following glucose ingestion presents a challenge because of the difficulties in quantitating the rate of glucose absorption, suppression of hepatic glucose production, and organ (liver and muscle) glucose uptake. Moreover, because the plasma glucose and insulin concentrations are changing simultaneously, it is difficult to draw conclusions about insulin secretion or insulin sensitivity.


To address these issues, Ferrannini, DeFronzo, and colleagues (7,11,12,205) administered oral glucose to healthy control subjects in combination with hepatic vein catheterization to examine splanchnic glucose metabolism. The oral glucose load and endogenous glucose pool were labeled with [1-14C]glucose and [3-3H]glucose, respectively, to quantitate total body glucose disposal (from tritiated glucose turnover) and endogenous HGP (difference between the total rate of glucose appearance, as measured with tritiated glucose, and the rate of oral glucose appearance, as measured with [1-14C]glucose).


During the 3.5 h after glucose (68 g) ingestion: (i) 19 g, or 28%, or the oral load was taken up by splanchnic tissues; (ii) 48 g, or 72%, was disposed of by peripheral (non-splanchnic) tissues; (iii) of the 48 g taken up by peripheral tissues, the brain (an insulin-independent tissue) accounted for ~15 g (~1 mgokg-1omin-1), or 22%, of the total glucose load (12); (iv) basal HGP declined by 53%. Similar percentages for splanchnic glucose uptake (24%-29%) and suppression of HGP (50%-60%) in normal subjects have been reported by other investigators (13,204,207-209). The contribution of skeletal muscle to the disposal of an oral glucose load has been reported to vary from a low of 26% (207) to a high of 56% (208), with a mean of 45% (11,13,207-209). These results emphasize several important differences between oral and intravenous glucose administration. After glucose ingestion: (i) HGP is less completely suppressed, most likely do to activation of local sympathetic nerves that innervate the liver (210); (ii) peripheral tissue (primarily muscle) glucose uptake is quantitatively less important; (3) splanchnic glucose uptake is quantitatively much more important.


In type 2 diabetic individuals (12,204,205,211,212) the disposition of an oral glucose load is significantly altered. The disturbance in glucose metabolism is accounted for by two factors: (i) decreased tissue glucose uptake and (ii) impaired suppression of HGP. Splanchnic glucose uptake is similar in diabetic and control groups. Inappropriate suppression of HGP accounted for approximately one-third of the defect in total-body glucose homeostasis, while reduced peripheral (muscle) glucose uptake accounted for the remaining two-thirds. Since hyperglycemia per se enhances splanchnic (hepatic) glucose uptake in proportion to the increase in plasma glucose concentration (24,175), the splanchnic glucose clearance (SGU ÷ plasma glucose concentration) is markedly reduced in all type 2 diabetic subjects following glucose ingestion. Using a combined insulin clamp/OGTT technique, an impairment in glucose uptake by the splanchnic tissues in type 2 diabetics has been demonstrated directly (213).


When viewed in absolute terms, most studies have demonstrated that the total amount of glucose taken up by all tissues of body over the 4 hour period following the ingestion of an oral glucose load is normal (13) or slightly decreased (204,205,211). However, this occurs at the expense of postprandial hyperglycemia. Thus, the efficiency of glucose disposal, i.e., the glucose clearance (tissue glucose uptake ÷ plasma glucose concentration), is severely reduced. It should be emphasized that it is not the absolute glucose disposal rate, but rather the increment in glucose disposal above baseline that determines the rise in plasma glucose concentration above the fasting value. Every published study (13,204,205,211) has demonstrated that the incremental response in whole-body glucose uptake is moderately to severely reduced in type 2 diabetic individuals. Similar results have been reported for forearm muscle glucose uptake (13,201,202,208,209) , pointing out the important contribution of diminished muscle glucose disposal to impaired oral glucose tolerance in type 2 diabetes.


In summary, results of the OGTT indicate that both impaired suppression of HGP and decreased tissue (muscle) glucose uptake contribute approximately equally to the glucose intolerance of type 2 diabetes. The efficiency of the splanchnic (hepatic) tissues to take up glucose (as reflected by the splanchnic glucose clearance) also is impaired in type 2 diabetic individuals.



Summary of Insulin Resistance in Type 2 Diabetes

Insulin resistance involving both muscle and liver are characteristic features of the glucose intolerance in type 2 diabetic individuals. In the basal state, the liver represents a major site of insulin resistance, and this is reflected by overproduction of glucose despite the presence of both fasting hyperinsulinemia and hyperglycemia. This accelerated rate of hepatic glucose output is the primary determinant of the elevated fasting plasma glucose concentration in type 2 diabetic individuals. Although tissue (muscle) glucose uptake in the postabsorptive state is increased when viewed in absolute terms, the efficiency with which glucose is taken up (i.e., the glucose clearance) is diminished. After glucose infusion or ingestion (i.e., in the insulin stimulated state), both decreased muscle glucose uptake and impaired suppression of HGP contribute to the insulin resistance. Following glucose ingestion, the defects in insulin-mediated glucose uptake by muscle and the suppression of HGP by insulin contribute approximately equally to the disturbance in whole-body glucose homeostasis in type 2 diabetes. However, under euglycemic hyperinsulinemic conditions, HPG is largely suppressed and impaired muscle glucose uptake is primarily responsible for the insulin resistance.




Type 2 diabetic subjects manifest abnormalities both in tissue (muscle, fat, and liver) sensitivity to insulin and in pancreatic insulin secretion. To understand how these two metabolic disturbances interact to produce the full-blown diabetic condition, it is necessary to quantitate insulin action and insulin secretion in the same individual over a wide range of insulin sensitivity. This dynamic interaction is demonstrated graphically by results obtained in healthy, lean, young normal glucose tolerant women who received a euglycemic insulin clamp (1 mUokg-1omin-1) and were stratified into quartiles based upon the rate of insulin-mediated glucose disposal (49) . Insulin secretion was measured independently on a separate day with a +125 mg/dl hyperglycemic clamp . Insulin resistance and insulin secretion were strongly and positively correlated (r=0.79, p<0.001). Women who were the most insulin resistant (quartile 1) had the highest fasting plasma insulin concentrations and highest early and late phase plasma insulin responses . Similar results relating the plasma insulin response and the severity of insulin resistance have been reported in normal glucose tolerant subjects with the minimal model technique (46,47) and the insulin suppression test/oral glucose tolerance test (214).


A number of groups have examined the dynamic interaction between insulin secretion and insulin sensitivity in type 2 diabetic subjects (1,4,34,35,38,39,42,46-48,58-61,150,162). DeFronzo (4) studied lean (ideal body weight < 120%) and obese (ideal body weight > 125%) subjects with varying degrees of glucose tolerance as follows: Group I-obese subjects (n=24) with normal glucose tolerance; Group II-obese subjects (n=23) with impaired glucose tolerance; Group III-obese subjects (n=35) with overt diabetes, subdivided into those with a hyperinsulinemic response and those with a hypoinsulinemic response during a 100-gram OGTT; Group IV-normal weight type 2 diabetics (n=26); Group V-normal weight subjects (n=25) with normal glucose tolerance. All subjects ingested 100 g of glucose to provide a measure of glucose tolerance and insulin secretion. Whole-body insulin sensitivity was quantitated with the euglycemic insulin (~100 µU/ml) clamp technique, which was performed with indirect calorimetry to quantitate rates of glucose oxidation and nonoxidative glucose disposal. The later primarily reflects glycogen synthesis (215).


In normal weight type 2 diabetic subjects, insulin-mediated whole-body glucose uptake was reduced by 40-50% and the impairment in insulin action resulted from defects in both oxidative and nonoxidative glucose metabolism (4) . Obese nondiabetic individuals were as insulin resistant as the normal-weight diabetic subjects (4) . Defects in both glucose oxidation and glucose storage contributed to the insulin resistance in the obese nondiabetic group . From the metabolic standpoint, therefore, obesity and type 2 diabetes closely resemble each other. Similar results concerning reduced whole-body insulin sensitivity in obese and type 2 diabetic individuals have been reported by other investigators (160,161,166,216-218). Despite nearly identical degrees of insulin resistance, normal-weight diabetic subjects manifested fasting hyperglycemia and marked glucose intolerance, whereas the obese nondiabetic individuals had normal or only minimally impaired oral glucose tolerance (4). This apparent paradox is explained by the plasma insulin response during the OGTT . Compared with control subjects, the obese nondiabetic group secreted more than twice as much insulin, and this was sufficient to offset the insulin resistance. In contrast, in normal-weight diabetic subjects, the pancreas, when faced with the same challenge, was unable to augment its secretion of insulin sufficiently to compensate for the insulin resistance. This imbalance between insulin supply by the ß-cells and the insulin requirement by tissues resulted in a frankly diabetic state, with fasting hyperglycemia and marked glucose intolerance.


When obesity and diabetes coexist in the same individual, the severity of insulin resistance is only slightly greater than that in either the normal-weight diabetic or nondiabetic obese groups (4) , and the magnitude of the defects in glucose oxidation and nonoxidative glucose disposal are similar in all obese and diabetic groups . Although hyperinsulinemic and hypoinuslinemic obese diabetic subjects were equally insulin resistant, the severity of glucose intolerance is worse in the hypoinsulinemic group, and this was related entirely to the presence of severe insulin deficiency .


An integrated summary of insulin action and insulin secretion in obese, diabetic, and lean groups is presented in figure 4 (coming soon). The plasma insulin response during the OGTT is shown in the top panel, along with the rate of insulin-mediated glucose disposal. In the obese nondiabetic subjects, tissue sensitivity to insulin is markedly reduced, but glucose tolerance remains perfectly normal because the ß-cells are able to augment their insulin secretory capacity appropriately to offset the defect in insulin action. As the obese individual develops impaired intolerance, there is a further reduction in insulin-mediated glucose disposal, which is due primarily to a decrease in glycogen synthesis. However, there is only a small additional impairment in glucose tolerance, because the ß-cells are able to augment further their secretion of insulin to counteract the deterioration in insulin sensitivity. The progression of the obese, glucose intolerant person to overt diabetes is heralded by a decline in insulin secretion without any worsening of insulin resistance . The obese diabetic has tipped over the top of Starling's curve of the pancreas and is now on the descending portion . Even though the plasma insulin response is increased compared to nondiabetic control subjects, it is not elevated appropriately for the degree of insulin resistance. In the normal-weight diabetic group, there is a further decline in glucose tolerance, which results from a greater impairment in insulin secretion without any additional deterioration in insulin sensitivity. Lastly, the obese diabetic group with a low insulin response manifests the greatest glucose intolerance, due to the presence of marked insulin deficiency without any further worsening of insulin sensitivity .


The natural history of type 2 diabetes described above is consistent with results in humans and monkeys published by other investigators (33-39,42,43,59-61,98,150). In lean subjects with a wide range of glucose tolerance, Reaven et al (42) demonstrated that the progression from normal to impaired glucose tolerance was marked by the development of severe insulin resistance, which was counterbalanced by a compensatory increase in insulin secretion. The onset of type 2 diabetes was associated with no (or only slight) further deterioration in tissue sensitivity to insulin . Rather, insulin secretion declined and the impairment in beta cell function was paralleled by a decrease in glucose tolerance . A similar sequence of events has been documented prospectively in Pima Indians (34-39,58,60). The sequence of events described in Caucasians (1,4,41,42,44,47,59,162,219), Pima Indians (34-39,58,60,219), and Pacific Islanders (33,62,220) is consistent with the development of type 2 diabetes in the rhesus monkeys (48). As monkeys grows older, they become obese and develop a diabetic condition closely resembling human type 2 diabetes. The earliest detectable abnormality in this primate model is a decrease in tissue sensitivity to insulin. Because of a compensatory increase in insulin secretion, the fasting plasma glucose concentration and glucose tolerance remain normal.


The studies detailed above indicate that insulin resistance is an early and characteristic feature of the natural history of type 2 diabetes in high risk populations. Overt diabetes develops only in those individuals whose beta cells are unable to appropriately augment their secretion of insulin to compensate for the defect in insulin action. It should be recognized, however, that there are well-described type 2 diabetic populations in whom insulin sensitivity is normal at the onset of diabetes, whereas insulin secretion is severely impaired (81-83). How frequently this occurs in typical type 2 diabetic patients remains to be determined. This insulinopenic variety of type 2 diabetes appears to be more common in African-Americans, elderly subjects, and lean Caucasians. In this later group, it is important to exclude type 1 diabetes, since ~10% of Caucasian individuals with older onset diabetes are islet cell antibody and/or GAD positive (220).



The majority (>80%) of type 2 diabetics in the US are overweight (221). Both lean and especially obese type 2 diabetics are characterized by day-long elevations in the plasma free fatty acid concentration, which fail to suppress normally following ingestion of a mixed meal or oral glucose load (222). Free fatty acids (FFA) are stored as triglycerides in adipocytes and serve as an important energy source during conditions of fasting. Insulin is a potent inhibitor of lipolysis, and restrains the release of FFA from the adipocyte by inhibiting the enzyme hormone sensitive lipase. In type 2 diabetics the ability of insulin to inhibit lipolysis (as reflected by impaired suppression of radioactive palmitate turnover) and reduce the plasma FFA concentration is markedly reduced (17). It is now recognized that chronically elevated plasma FFA concentrations can lead to insulin resistance in muscle and liver (1,4,19,21,22,51,162,223,224) and impair insulin secretion (22,225,226) . Thus, elevated plasma FFA levels can cause/aggravate the three major pathogenic disturbances that are responsible for impaired glucose homeostasis in type 2 diabetic individuals and the time has arrived for the "triumvirate" (muscle, liver, beta cell) to be joined by the "fourth musketeer" (227) to form the "harmonious quartet" . In addition to FFA that circulate in plasma in increased amounts, type 2 diabetic and obese nondiabetic individuals have increased stores of triglycerides in muscle (228,229) and liver (230,231) and the increased fat content correlates closely with the presence of insulin resistance in these tissues. Triglycerides in liver and muscle are in a state of constant turnover and the metabolites (i.e., fatty acyl CoAs) of intracellular FFAs have been shown to impair insulin action in both liver and muscle (1,4,92) . This sequences of events has been referred to as "lipotoxicity" (1,4,22,93). Evidence also has accumulated to implicate "lipotoxicity" as an important cause of beta cell dysfunction (22,93) (see earlier discussion).


FFA and Muscle Glucose Metabolism

Four decades ago, Randle (232) proposed that increased FFA oxidation restrains glucose oxidation in muscle by altering the redox potential of the cell and by inhibiting key glycolytic enzymes . The excessive FFA oxidation: (i) leads to the intracellular accumulation of acetyl CoA, a potent inhibitor of pyruvate dehydrogenase (PDH), (ii) increases the NADH/NAD ratio, causing a slowing of the Krebs cycle, and (iii) results in the accumulation of citrate, a powerful inhibitor of phosphofructokinase (PFK). Inhibition of PFK leads to the accumulation of glucose-6-phosphate (G-6-P) which in turn inhibits hexokinase II. The block in glucose phosphorylation causes a build up of intracellular free glucose which restrains glucose transport into the cell via the GLUT4 transporter. The resultant decrease in glucose transport was postulated to account for the impairment in glycogen synthesis, although a direct inhibitory effect of fatty acyl CoAs on glycogen synthase also has been demonstrated (233). This sequence of events via which accelerated plasma FFA oxidation inhibits muscle glucose transport, glucose oxidation, and glycogen synthesis is referred to as the "Randle Cycle" (232). It should be noted that the same scenario would ensue if the FFA were derived from triglycerides stored in muscle (228,229) or from plasma (222).


Felber and coworkers (59,159,162,234,235) were amongst the first to demonstrate that in obese non-diabetic and diabetic humans, basal plasma FFA levels and lipid oxidation (measured by indirect calorimetry) are increased and fail to suppress normally after glucose ingestion. The elevated basal rate of lipid oxidation was strongly correlated with a decreased basal rate of glucose oxidation, as well as with reduced rates of glucose oxidation and non-oxidative glucose disposal (glycogen synthesis) following ingestion of a glucose load. Further validation of the Randle Cycle in man has come from studies employing the euglycemic insulin clamp. In normal subjects, physiologic hyperinsulinemia (80-100 uU/ml) causes a 60-70% decline in plasma FFA concentration and a parallel decline in plasma FFA and total body lipid oxidation (18). When Intralipid is infused concomitantly with insulin to maintain or increase the plasma FFA concentration/oxidation, both glucose oxidation and non-oxidative glucose disposal are inhibited in a dose dependent fashion (223). Using magnetic resonance imaging, it has been shown that the FFA-induced inhibition of non-oxidative glucose disposal reflects impaired glycogen synthesis (236). The inhibitory effect of elevated plasma FFA levels can be observed at all plasma insulin concentrations, spawning the physiologic and pharmacologic range (223).

The inhibitory effect of an acute elevation in plasma FFA concentration on muscle glucose metabolism is time dependent. Thus, the earliest (within 2 hours) observed abnormality is a defect in glucose oxidation (237), as would be predicted by operation of the Randle cycle (232). This is followed (between 2-3 hours) by defects in glucose transport and phosphorylation and eventually (after 3-4 hours) by impaired glycogen synthesis.


Randle Cycle Revisited: Biochemical/Molecular Basis Of FFA-Induced Insulin Resistance

The original description of the Randle cycle was formulated based upon experiments performed in rat diaphragm and heart muscle (232). More recent studies performed in human skeletal muscle suggest that mechanisms in addition to those originally proposed by Randle are involved in the FFA-induced insulin resistance. Thus, several groups (236,238,239) have failed to observe a rise in muscle G-6-P and citrate concentrations when insulin-stimulated glucose metabolism was inhibited by an increase in the plasma FFA concentration. Elevated plasma FFA levels also failed to inhibit muscle phosphofructokinase activity. Thus, while increased FFA/lipid oxidation and decreased glucose oxidation are closely coupled, as originally demonstrated by Randle, mechanisms other than product (i.e., elevated intracellular G-6-P and free glucose concentrations) inhibition of the early steps of glucose metabolism must be invoked to explain the defects in glucose transport, glucose phosphorylation and glycogen synthesis.

Studies in humans and animals have shown a strong inverse correlation between insulin-stimulated glucose metabolism and increased intramuscular lipid pools, including triglyceride (240-242), diacylglycerol (DAG) (243,244), and long chain fatty acyl CoAs (FA-CoA) (245). An acute elevation in plasma FFA concentration leads to an increase in muscle fatty acyl CoA and DAG concentrations. Both long chain fatty acyl CoAs and DAG activate PKC theta (243), which increases serine phosphorylation with subsequent inhibition of IRS-1 tyrosine phosphorylation (246,247). Consistent with this observation, two groups have shown that in human muscle elevated plasma FFA levels inhibit insulin-stimulated tyrosine phosphorylation of IRS-1, the association of the p85 subunit of PI-3 kinase with IRS-1, and activation of PI-3-kinase (248,249) . Direct effects of long chain fatty acyl CoAs on glucose transport (250), glucose phosphorylation (251), and glycogen synthase (233) also have been demonstrated in muscle . Lastly, increased muscle ceramide levels (secondary to increased long chain fatty acyl CoAs) have been shown to interfere with glucose transport and to inhibit glycogen synthase in muscle via activation of PKB (252). In summary, elevated plasma FFA concentrations can induce insulin resistance in muscle via multiple mechanisms involving alterations in a variety of intracellular lipid signaling molecules which exert their inhibitory effects on multiple steps (insulin signal transduction system, glucose transport, glucose phosphorylation, glycogen synthase, pyruvate dehydrogenase, Krebs cycle) involved in glucose metabolism.


FFA and Blood Flow

Insulin is a vasodilatory hormone and the stimulatory effect of insulin on muscle glucose metabolism has been shown to result from: (i) a direct action of insulin to augment muscle glucose metabolism, and (ii) increased blood flow to muscle (253,254). The vasodilatory effect of insulin is mediated via the release of nitric oxide from the vascular endothelium (255). In insulin resistant conditions, such as obesity and type 2 diabetes, some investigators have suggested that as much as half of the impairment in insulin-mediated whole body and leg muscle glucose uptake is related to a defect in insulin's vasodilatory action (253,254) , although the link between insulin-mediated vasodilation and increased blood flow has been challenged by others (256).


Because type 2 diabetes and obesity are insulin resistant states characterized by day-long elevation in the plasma FFA concentration (222) and impaired endothelium dependent vasodilation (253), investigators have examined the effect of increased plasma FFA levels on limb blood flow and muscle glucose uptake (257,258). In healthy, non-diabetic subjects an acute physiologic increase in plasma FFA concentration inhibited methacholine (endothelium dependent) but not nitroprusside (endothelium independent) stimulated blood flow in association with an impairment in insulin-stimulated muscle glucose disposal. In subsequent studies, the inhibitory effect of FFA on insulin-stimulated leg blood flow was shown to be associated with decreased nitric oxide production (259). FFA elevation also inhibits nitric oxide production in endothelial cell cultures by decreasing nitric oxide synthase activity (259). Since the IRS-1/PI-3 kinase signal transduction pathway is involved in the regulation of nitric oxide synthase activity (260), one could hypothesize that FFA-induced inhibition of the insulin signal transduction pathway is responsible for the blunted vasodilatory response to the hormone.


FFA and Hepatic Glucose Metabolism

The liver plays a pivotal role in the regulation of glucose metabolism (1,4,6,11,16,205). Following carbohydrate ingestion, the liver suppresses its basal rate of glucose production takes up approximately one-third of the glucose in the ingested meal (12,24,25,205). Collectively, suppression of hepatic glucose production and augmentation of hepatic glucose uptake account for the maintenance of about half of the rise in plasma glucose concentration following ingestion of a carbohydrate meal.

Hepatic glucose production is regulated by a number of factors , of which insulin (inhibits HGP) and glucagon and FFA (stimulate HGP) are the most important. In vitro studies have demonstrated that plasma FFA are potent stimulators of HGP and do so by increasing the activity of pyruvate carboxylase and phosphoenolpyruvate carboxykinase, the rate limiting enzymes for gluconeogenesis (261,262). FFA also enhance the activity of glucose-6-phosphatase, the enzyme that ultimately controls the release of glucose by the liver (263).

In normal subjects, increase plasma FFA levels stimulate gluconeogenesis (264,265), while a decrease in plasma FFA concentration reduces gluconeogenesis (264). It has documented that a significant portion of the suppressive effect of insulin on hepatic glucose production is mediated via inhibition of lipolysis and a reduction in circulating plasma FFA concentrations (16,266,267). Moreover, FFA infusion in normal humans under conditions that simulate the diabetic state (268) and in obese insulin-resistant subjects (269) enhances hepatic glucose production, most likely secondarily to stimulation of gluconeogenesis.


In type 2 diabetic subjects, the fasting plasma FFA concentration and lipid oxidation rate are increased and are strongly correlated with both the elevated fasting plasma glucose concentration and basal rate of hepatic glucose production (18,51,59,162,190,270). The relationship between elevated plasma FFA concentration, FFA oxidation, and hepatic glucose production in obesity and type 2 diabetes is explained as follows: (i) increased plasma FFA levels, by mass action, augment FFA uptake by hepatocytes, leading to accelerated lipid oxidation and accumulation of acetyl CoA. The increased concentration of acetyl CoA stimulates pyruvate carboxylase, the rate limiting enzyme in gluconeogenesis (261,262), as well as glucose-6-phosphatase, the rate-controlling enzyme for glucose release from the hepatocyte (263); (ii) the increased rate of FFA oxidation provides a continuing source of energy (in the form of ATP) and reduced nucleotides (NADH) to drive gluconeogenesis; (iii) elevated plasma FFA induce hepatic insulin resistance by inhibiting the insulin signal transduction system (244-248). In type 2 diabetic patients these deleterious effects of elevated plasma FFA concentrations occur in concert with increased plasma glucagon levels (181,190,271), increased hepatic sensitivity to glucagon, and increased hepatic uptake of circulating gluconeogenic precursors.


Summary: FFA and the Pathogenesis of Obesity and Type 2 Diabetes Mellitus

In obese individuals and in the majority (>80%) of type 2 diabetic subjects, there is an expanded fat cell mass and the adipocytes are resistant to the antilipolytic effects of insulin (18). Most obese and diabetic individuals are characterized by visceral adipocity (272) and visceral fat cells have a high lipolytic rate, which is especially refractory to insulin (273). Not surprisingly, both type 2 diabetes and obesity are characterized by an elevation in the mean day-long plasma FFA concentration. Elevated plasma FFA levels, as well as increased triglyceride/fatty acyl CoA content in muscle, liver, and beta cell, lead to the development of muscle/hepatic insulin resistance and impaired insulin secretion.



The stimulation of glucose metabolism by insulin, requires that the hormone must first bind to specific receptors that are present on the cell surface of all insulin target tissues (1,274-277). After insulin has bound to and activated its receptor, "second messengers" are generated and these second messengers initiate a series of events involving a cascade of phosphorylation-dephosphorylation reactions (1,274-280) that eventually result in the stimulation of intracellular glucose metabolism. The initial step in glucose metabolism involves activation of the glucose transport system, leading to influx of glucose into insulin target tissues, primarily muscle (1,281,282). The free glucose, which has entered the cell, subsequently is metabolized by a series of enzymatic steps that are under the control of insulin. Of these, the most important are glucose phosphorylation (catalyzed by hexokinase), glycogen synthase (which controls glycogen synthesis), and phosphofructokinase (PFK) and PDH (which regulate glycolysis and glucose oxidation, respectively).


Insulin Receptor/Insulin Receptor Tyrosine Kinase

The insulin receptor is a glycoprotein consisting of two a-subunits and two ß-subunits linked by disulfide bonds (1,274-277) . The a-subunit of the insulin receptor is entirely extracellular and contains the insulin-binding domain. The ß-subunit has an extracellular domain, a transmembrane domain, and an intracellular domain that expresses insulin-stimulated kinase activity directed towards its own tyrosine residues (1,274-277). Insulin receptor phosphorylation of the ß-subunit, with subsequent activation of insulin receptor tyrosine kinase, represents the first step in the action of insulin on glucose metabolism (274-277). Mutagenesis experiments have shown that insulin receptors devoid of tyrosine kinase activity are completely ineffective in mediating insulin stimulation of cellular metabolism (283,284). Similarly, mutagenesis of any of the three major phosphorylation sites (at residues 1158, 1163, and 1162) impairs insulin receptor kinase activity, resulting in a decrease in the acute metabolic and growth promoting effects of insulin (283,285).


Insulin Receptor Signal Transduction

Following activation, insulin receptor tyrosine kinase phosphorylates specific intracellular proteins, of which at least nine have been identified (282). Four of these belong to the family of insulin-receptor substrate proteins: IRS-1, IRS-2, IRS-3, IRS-4 (the others include Shc, Cbl, Gab-1, p60dok, and APS). In muscle IRS-1 serves as the major docking protein that interacts with the insulin receptor tyrosine kinase and undergoes tyrosine phosphorylation in regions containing amino acid sequence motifs (YXXM or YMXM) that, when phosphorylated, serve as recognition sites for proteins containing src-homology 2 (SH2) domains (where y = tyrosine, M = methionine, and x - any amino acid) (274,275). Mutation of these specific tyrosines severely impairs the ability of insulin to stimulate glycogen and DNA synthesis, establishing the important role of IRS-1 in insulin signal transduction (282). In liver, IRS-2 serves as the primary docking protein that undergoes tyrosine phosphorylation and mediates the effect of insulin on hepatic glucose production, gluconeogenesis and glycogen formation (287). In adipoctes, Cbl represents another substrate which is phosphorylated following its interaction with the insulin receptor tyrosine kinase and which is required for stimulation of GLUT 4 transloctaion. Phosphorylation of Cbl occurs when the CAP/Cbl complex associates with flotillin in caveolae, or lipid rafts, containing insulin receptors (288,289).


In muscle, the phosphorylated tyrosine residues on IRS-1 mediate an association between the two SH2 domains of the 85-kDa regulatory subunit of phosphatidylinositol 3-kinase (PI3-kinase), leading to activation of the enzyme (274-284,290,291) . PI3-kinase is a heterodimeric enzyme comprised of an 85-kDa regulatory subunit and a 110-kDa catalytic subunit. The latter catalyzes the 3-prime phosphorylation of phosphatidylinositol (PI), PI-4-phosphate, and PI-4,5-diphosphate, resulting in the stimulation of glucose transport (274-277). Activation of PI3-kinase by phosphorylated IRS-1 also leads to activation of glycogen synthase (274,275), via a process that involves activation of PKB/Akt and subsequent inhibition of kinases such as GSK-3 (292) and activation of protein phosphatase 1 (PP1) (293). Inhibitors of PI3-kinase impair glucose transport (274-277,294) by interfering with the translocation of GLUT 4 transporters from their intracellular location (281,282) and block the activation of glycogen synthase (295) and hexokinase (HK)-II expression (296). The action of insulin to increase protein synthesis and inhibit protein degradation also is mediated by PI-3 kinase and involves the activation of mTOR (297,298). mTOR controls translation machinery by phosphorylation and activation of p70 ribosomal S6 kinase (p70rsk) (297) and phosphorylation of initiation factors (299). Insulin also promotes hepatic triglyceride synthesis via increasing the transcription factor steroid regulatory element-binding protein (SREBP)-1c (300) and this lipogenic effect of insulin also appears to be mediated via the PI3-kinase pathway (274).


Other proteins with SH2 domains, including the adapter protein Grb2 and Shc, also interact with IRS-1 and become phosphorylated following exposure to insulin (274-276,301). Grb2 and Shc serve to link IRS-1/IRS-2 to the mitogen-activated protein (MAP) signaling pathway , which plays an important role in the generation of transcription factors (274,275). Following the interaction between IRS-1/IRS-2 and Grb2 and Shc, Ras is activated, leading to the stepwise activation of Raf, MEK, and ERK. Activated ERK than translocates into the nucleus of the cell where it catalyzes the phosphorylation of transcription factors which promote cell growth, proliferation, and differentiation (274-276,301-303). Blockade of the MAP kinase pathway prevents the stimulation of cell growth by insulin but has no effect on the metabolic actions of the hormone (304-306).

Under anabolic conditions insulin stimulates glycogen synthesis by simultaneously activating glycogen synthase and inhibiting glycogen phosphorylase (307-309). The effect of insulin is mediated via the PI3 kinase pathway which inactivates kinases such as glycogen synthase kinase-3 and activates phosphatases, particularly protein phosphatase 1 (PP1). It is believed that PP1 is the primary regulator of glycogen metabolism (307-310). In skeletal muscle, PP1 associates with a specific glycogen-binding regulatory subunit, causing dephosphorylation (activation) of glycogen synthase. PP1 also phosphorylates (inactivates) glycogen phosphorylase. The precise steps that link insulin receptor tyrosine kinase/PI 3-kinase activation to stimulation of PP1 have yet to be defined. Some evidence suggests that p90 ribosomal S6-kinase may be involved in the activation of glycogen synthase (274). Akt also has been shown to phosphorylate and thus inactivate GSK-3 (292). This decreases glycogen synthase phosphorylation, leading to activation of the enzyme (292). A number of studies have convincingly demonstrated that inhibitors of PI3-kinase inhibit glycogen synthase activity and abolish glycogen synthesis (274,293,310). From the physiological standpoint, it makes sense that activation of glucose transport and glycogen synthase should be linked to the same signaling mechanism in order to provide a coordinated stimulation of intracellular glucose metabolism.


Insulin Signal Transduction Defects in Type 2 Diabetes

Insulin Receptor Number and Affinity

Both receptor and postreceptor defects have been shown to contribute to insulin resistance in type 2 diabetic individuals. Some, but not all studies have demonstrated a modest 20-30% reduction in insulin binding to monocytes and adipocytes from type 2 diabetic patients (1,311-316). This reduction is due to a decreased number of insulin receptors without change in insulin receptor affinity. In addition to the decreased number of cell-surface receptors, a variety of defects in insulin receptor internalization and processing have been described (314,315). However, some caution should be employed in interpreting these studies. Muscle and liver, not adipocytes, represent the major tissues responsible for the regulation of glucose homeostasis in vivo and insulin biding to solubilized receptors obtained from skeletal muscle biopsies and liver has been shown to be normal in obese and lean diabetic individuals when expressed per milligram of protein (312,313,316-318). Moreover, a decrease in insulin receptor number cannot be demonstrated in over half of type 2 diabetic subjects (319,320), and it has been difficult to demonstrate a correlation between reduced insulin binding and the severity of insulin resistance (321,322). The insulin receptor gene has been sequenced in a large number of type 2 diabetic patients from diverse ethnic populations using denaturing-gradient gel electrophoresis or single-stranded conformational polymorphism analysis, and, with very rare exceptions (323), physiologically significant mutations in the insulin receptor gene have not been observed (324,325). This excludes a structural gene abnormality in the insulin receptor as a cause of common type 2 diabetes mellitus.

Insulin Receptor Tyrosine Kinase Activity

Insulin receptor tyrosine kinase activity has been examined in a variety of cell types (skeletal muscle, adipocytes, hepatocytes, and erythrocytes) from normal-weight and obese diabetic subjects. Most (278,301,312,313,320,326-328), but not all (317,329) investigators have found reduced tyrosine kinase activity that cannot be explained by alterations in insulin receptor number or insulin receptor binding. However, near-normalization of the fasting plasma glucose concentration, (by weight loss) has been reported to correct the defect in insulin receptor tyrosine kinase activity (330). This observation suggests that the defect in tyrosine kinase is acquired and results from some combination of hyperglycemia, defective intracellular glucose metabolism, hyperinsulinemia, and insulin resistance - all of which improved after weight loss. A glucose-induced reduction in insulin receptor tyrosine kinase activity has been demonstrated in rat fibroblast culture in vitro (331). Insulin receptor tyrosine kinase activity assays are performed in vitro, and the results of these assays could provide misleading information with regard to insulin receptor function in vivo. To circumvent this problem, investigators have employed the euglycemic hyperinsulinemic clamp in combination with muscle biopsies and anti-phosphotyrosine immunoblot analysis (301). Such analysis yields a "snap shot" of the insulin-stimulated tyrosine phosphorylation state of the receptor in vivo. The results of these studies have demonstrated a substantial decrease in insulin receptor tyrosine phosphorylation in both obese nondiabetic and type 2 diabetic subjects (301,328). When insulin-stimulated insulin receptor tyrosine phosphorylation was examined in normal-glucose-tolerant or impaired-glucose-tolerant individuals at high risk of developing type 2 diabetes, a normal increase in tyrosine phosphorylation of the insulin receptor has been observed (332). These observations are consistent with the concept that impaired insulin receptor tyrosine kinase activity in type 2 diabetic patients is acquired secondarily to hyperglycemia or some other metabolic disturbance.

Insulin Signaling (IRS-1 and PI-3 kinase) Defects

A physiologic increase in the plasma insulin concentration stimulates tyrosine phosphorylation of the insulin receptor and IRS-1 in lean healthy subjects to 150-200% of basal values (280,301,328,332,333). In obese nondiabetic subjects, the ability of insulin to activate these two early insulin receptor signaling events in muscle is reduced, while in type 2 diabetics insulin has no significant stimulatory effect on either insulin receptor or IRS-1 tyrosine phosphorylation (301) . The association of p85 protein and PI3-kinase activity with IRS-1 also is greatly reduced in obese non-diabetic and type 2 diabetic subjects compared to lean healthy subjects (301,328-334) . Insulin also failed to increase the association of the p85 subunit of PI3-kinase with IRS-2 in muscle, indicating that type 2 diabetes is characterized by a combined defect in IRS-1 and IRS-2 function (301,328). The decrease in insulin stimulation of the association of the p85 regulatory subunit of PI3-kinase with IRS-1 is closely correlated with the impairment in muscle glycogen synthase activity and in vivo insulin-stimulated glucose disposal (301). Defective regulation of PI3-kinase gene expression by insulin also has been demonstrated in skeletal muscle and adipose tissue of type 2 diabetic subjects (335). In animal models of diabetes, an 80% decrease in IRS-1 phosphorylation and a greater than 90% reduction in insulin-stimulated PI3-kinase activity have been reported (336).


In the insulin resistant, normal glucose tolerant offspring of two type 2 diabetic parents, IRS-1 tyrosine phosphorylation and the association of p85 protein/PI3-kinase activity with IRS-1 are markedly decreased despite normal tyrosine phosphorylation of the insulin receptor; these insulin signaling defects are correlated closely with the severity of insulin resistance, measured with the euglycemic insulin clamp technique (332). In summary, a defect in the association of PI3-kinase with IRS-1 and its subsequent activation appears to be a characteristic abnormality in type 2 diabetics, is closely correlated with in vivo muscle insulin resistance, and is unrelated to a disturbance in insulin receptor tyrosine phosphorylation. Several groups (337,338) have reported that a common mutation in the IRS-1 gene (Gly 972 Arg) is associated with type 2 diabetes, insulin resistance, and obesity, but the physiologic significance of this mutation remains to be established (339).


The profound insulin resistance of the PI3-kinase signaling pathway contrasts markedly with the ability of insulin to stimulate MAP kinase pathway activity in insulin-resistant type 2 diabetic and obese non-diabetics individuals (301,328). Hyperinsulinemia increases MEK1 activity and ERK1/2 phosphorylation and activity to the same extent in lean healthy as in insulin resistant obese nondiabetic and type 2 diabetic patients (301,328). This finding of selective insulin resistance is similar to that recently observed in vasculature of Zucker fatty rats (340). Two possible reasons for this difference are alternate insulin signaling pathways and differential signal amplification. With regard to the former, the MAP kinase pathway can be activated either through Grb2/Sos interaction with IRS-1/IRS-2 or with Shc. Because IRS-1 tyrosine phosphorylation is dramatically reduced in the diabetics, it is possible that insulin activation of the MAP kinase pathway in vivo primarily occurs through Shc activation. There is evidence from in vitro studies to support this concept (341). Like ERK and MEK activity, insulin increased Shc phosphorylation to the same extent in lean and obese nondiabetic and type 2 diabetic subjects (301). These results indicate that, in type 2 diabetes, insulin induces sufficient activation of the insulin receptor tyrosine kinase to increase Shc phosphorylation normally. It also is possible that differential signal amplification in the PI3-kinase and MAP kinase pathways can explain their differing susceptibilities to the effects of insulin resistance.

Maintenance of insulin stimulation of the MAP kinase pathway in the presence of insulin resistance in the PI3-kinase pathway may be important in the development of insulin resistance. ERKs can phosphorylate IRS-1 on serine residues (342), and serine phosphorylation of IRS-1 and the insulin receptor itself has been implicated in desensitizion insulin receptor signaling (343). Continued ERK activity, when IRS-1 function already is impaired, could lead to a worsening of insulin resistance. Thus, diabetic and obese subjects have inappropriately high MAP kinase activity. One also could postulate that insulin resistance in the metabolic (PI3-kinase) pathway, with its compensatory increase in beta cell function and hyperinsulinemia, leads to excessive stimulation of the MAP kinase pathway in vascular tissue (301,302). This would result in the proliferation of vascular smooth muscle cells, increased collagen formation, and increased production of growth factors and inflammatory cytokines, possibly explaining the accelerated rate of atherosclerosis in type 2 diabetic individuals.


Glucose Transport

Activation of the insulin signal transduction system in insulin target tissues leads to the stimulation of glucose transport. The effect of insulin is brought about by the translocation of a large intracellular pool of glucose transporters (associated with low-density microsomes) to the plasma membrane (281,282,344). There are five major, different facilitative glucose transporters with distinctive tissue distributions (281,282,345,346) (Table 2). GLUT4, the insulin regulatable transporter, is found in insulin-sensitive tissues (muscle and adipocytes), has a Km of ~5 mmol/l which is close to that of the plasma glucose concentration, and is associated with HK-II (347-349). In adipocytes and muscle, its concentration in the plasma membrane increases markedly after exposure to insulin, and this increase is associated with a reciprocal decline in the intracellular GLUT4 pool. GLUT1 represents the predominant glucose transporter in the insulin-independent tissues (brain and erythrocytes), but also is found in muscle and adipocytes. It is located primarily in the plasma membrane, where its concentration changes little after the addition of insulin. It has a low Km (~1 mmol/l) and is well suited for its function, which is to mediate basal glucose uptake. It is found in association with HKI (347-349). GLUT2 predominates in the liver and pancreatic ß-cells, where it is found in association with a specific hexokinase, HKIV (347-350). In the ß-cell, HKIV is referred to as glucokinase (350,351). GLUT2 has a high Km, (~15-20 mmol/l) and, as a consequence, the glucose concentration in cells expressing this transporter rises in direct proportion to the increase in plasma glucose concentration. This characteristic allows these cells to respond as glucose sensors. In summary, each tissue has a specific glucose transporter and associated hexokinase, which allow it uniquely to carry out its specialized function to maintain whole-body glucose economy.



Table 2. Classification of glucose transport and HK activity according to their tissue distribution and functional regulation
Organ  Glucose transporter  HK computer  Classification
Brain  GLUT1  HK-I  Glucose dependent
Erythrocyte  GLUT1  HK-I  Glucose dependent
Adipocyte  GLUT4 HK-II  Insulin dependent
Muscle  GLUT4  HK-II  Insulin dependent
Liver  GLUT2  HK-IVL  Glucose sensor
GK ß-cell  GLUT2  HK-IVB (glucokinase)  Glucose sensor
Gut  GLUT3-symporter  Sodium dependent
Kidney  GLUT3-symporter  Sodium dependent
From DeFronzo, Diabetes Rev 5:177-269, 1997



Glucose transport activity in type 2 diabetic patints uniformly has been found to be decreased in adipocytes (281,282,320,351,352) and muscle (281,282,354-356). In adipocytes from type 2 diabetic human and rodent models of diabetes, there is a severe reduction in GLUT4 mRNA and protein, and the ability of insulin to elicit a normal translocation response and to activate the GLUT4 transporter after its insertion into the cell membrane is impaired (281,282,320,353,357). In contrast, muscle tissue obtained from lean and obese type 2 diabetic subjects exhibits normal or increased levels of GLUT4 mRNA expression and normal levels of GLUT4 protein (358-361). Moreover, acute (2- 4-h) physiological hyperinsulinemia does not increase the number of GLUT4 transporters in muscle in either healthy or type 2 diabetic subjects (358-361). Several studies have demonstrated an increase in muscle GLUT4 mRNA levels in response to insulin in control subjects (333,360), but not in diabetics (360), suggesting insulin resistance at the level of gene transcription. However, the physiological significance of the blunted increase in muscle GLUT4 mRNA levels in type 2 diabetic subjects is unclear, since both basal and insulin-stimulated GLUT4 protein levels are normal. Large populations of type 2 diabetics have been screened for mutations in the GLUT4 gene (362,363). Such mutations are very uncommon and, when detected, have been of questionable physiologic significance.


The results summarized above indicate that the gene (GLUT4) encoding the major insulin-responsive glucose transporter and its transcriptional/translational regultion are not impaired in type 2 diabetes. However, in contrast to the normal expression of GLUT4 protein and mRNA in muscle of type 2 diabetic subjects, every study that has examined adipose tissue has reported reduced basal and insulin-stimulated GLUT4 mRNA levels, decreased GLUT4 transporter number in all subcellular fractions, diminished GLUT4 translocation, and impaired intrinsic activity of GLUT4 (281,282,353,361,364). These observations demonstrate that GLUT4 expression in humans is subject to tissue-specific regulation. Although insulin does not increase GLUT 4 expression in muscle, it stimulates the translocation of GLUT4 transporters from their intracellular location to the cell membrane (354,365,366). In type 2 diabetic humans, the ability of insulin to stimulate GLUT4 translocation in muscle is impaired (354,367). Using a novel triple-tracer technique, the in vivo dose-response curve for the action of insulin on glucose transport in forearm skeletal muscle has been examined in nondiabetic and type 2 diabetic subjects (368-370). Insulin-stimulated inward muscle glucose transport is severely impaired in type 2 diabetic subjects who are studied under euglycemic conditions . The defect in glucose transport cannot be overcome by repeating the insulin clamp at each subject's normal fasting glucose (hyperglycemia) level . Since the number of GLUT4 transporters in the muscle of diabetic subjects is normal (358-361), impaired GLUT4 translocation (281,354,367) and decreased intrinsic activity of the glucose transporter (366,371) must be responsible for the defect in muscle glucose transport. Impaired in vivo muscle glucose transport in type 2 diabetics also has been demonstrated using MRI (372) and PET (373).



Glucose Phosphorylation

Glucose phosphorylation and glucose transport are tightly coupled phenomena (374). Isoenzymes of hexokinase (HKI-HKIV) catalyze the first committed intracellular step of glucose metabolism, the conversion of glucose to glucose-6-phosphate (G-6-P) (347-350,375) (Table 2). HKI, HKII, and HKIII are single-chain peptides that have a number of properties in common, including a very high affinity for glucose and product inhibition by G-6-P. HKIV, also called glucokinase, has a lower affinity for glucose and is not inhibited by G-6-P. Glucokinase (HKIVB) is believed to be the glucose sensor in the ß-cell, while HKIVL plays an important role in the regulation of hepatic glucose metabolism.

In both rat (375-377) and human (333,348,378-380)skeletal muscle, HKII transcription is regulated by insulin. HKI also is present in human skeletal muscle, but it is not regulated by insulin (378). In response to physiological euglycemic hyperinsulinemia, HKII cytosolic activity, protein content, and mRNA levels increase by 50-200% in healthy non-diabetic subjects (378,380) and this is associated with the translocation of hexokinase II from the cytosol to the mitochondria (381). In contrast, insulin has no effect on HK-I activity, protein content, or mRNA levels (378).


In forearm muscle, insulin-stimulated glucose transport (measured with the triple tracer technique) has been shown to be markedly impaired in lean type 2 diabetics (370) . However, since the rate of intracellular glucose phosphorylation was impaired to an even greater extent , insulin caused an increase in the intracellular free glucose concentration. By performing the insulin clamp at each diabetic's normal level of fasting hyperglycemia, normal rates of whole-body glucose disposal and a normal rate of glucose influx into muscle was elicited . However, the rate of intracellular glucose phosphorylation increased only modestly ; consequently, there was a dramatic rise in the free glucose concentration within the intracellular space that is accessible to glucose. These observations indicate that in type 2 diabetic individuals, while both glucose transport and glucose phosphorylation are severely resistant to the action of insulin, impaired glucose phosphorylation (HKII) appears to be the rate-limiting step for insulin action. A similar pattern of impaired muscle glucose phosphorylation and transport is present in the insulin-resistant, normal glucose-tolerant offspring of two diabetic parents (382). These results are consistent with dose-response studies using PET to evaluated glucose phosphorylation and transport in skeletal muscle of type 2 diabetics (373). They also are consistent with 31P-NMR studies (383) which demonstrate that, during hyperinsulinemia, muscle G-6-P concentrations decline in type 2 diabetic versus control subjects. However, subsequent studies using 31P-NMR in combination with 1-14C-glucose suggest that the defect in insulin-stimulated muscle glucose transport exceeds the defect in glucose phosphorylation and is responsible for the decline in muscle glucose-6-P concentration (372). Because of methodologic differences, the results of the triple tracer (370) and MRI (372) studies cannot be reconciled at present. Nonetheless, observations from these studies are consistent in demonstrating that the defects in glucose phosphorylation and glucose transport in muscle are established early in the natural history of type 2 diabetes and cannot be explained by glucose toxicity (91). Clear evidence that HKII activity is crucial for glucose uptake derives from studies in transgenic mice who overexpress HKII. In this model, HKII overexpressiion increased both insulin- and exercise-stimulated muscle glucose uptake (384).


In healthy nondiabetic subjects, physiologic hyperinsulinemia for as little as 2-4 hours increases muscle HKII activity, gene transcription, and translation (333,378). In lean type 2 diabetics insulin-stimulated HKII activity and mRNA levels are markedly reduced compared to controls (383,385) . Decreased basal muscle HKII activity and mRNA levels (385) and impaired insulin-stimulated HKII activity(379,380,386,387) in type 2 diabetic subjects have been reported by other investigators. A decrease in insulin-stimulated muscle HKII activity also has been described in subjects with IGT (388). Because of its central role in insulin-mediated muscle glucose metabolism, several groups have looked for point mutations in the HKII gene in individuals with type 2 diabetes (388-390). Although several nucleotide substitutions have been found, none have been located close to the glucose and ATP binding sites and none have been associated with insulin resistance. Thus, an abnormality in the HKII gene is unlikely to explain the inherited insulin resistance in common variety type 2 diabetes mellitus.



Glycogen Synthesis

After glucose is phosphorylated by hexokinsae II, it either can be converted to glycogen or enter the glycolytic pathway. Of the glucose that enters the glycolytic pathway, ~90% is oxidized. At low physiologic plasma insulin concentrations, glycogen synthesis and glucose oxidation are of approximately equal quantitative importance. With increasing plasma insulin concentrations, glycogen synthesis predominates (18,391). If the rate of glucose oxidation (determined by indirect calorimetry) is subtracted from the rate of whole-body insulin-mediated glucose disposal (determined from the insulin clamp), the difference represents nonoxidative glucose disposal (or glucose storage) (17,360), which primarily reflects glycogen synthesis (1,4,162,216,392). Glucose conversion to lipid accounts for <5% of total body glucose disposal (18,198,199) and less than 5-10% of the glucose taken up by muscle is released as lactate (5,393,394). Reduced insulin-stimulated glycogen synthesis is a characteristic finding in all insulin-resistant states, including obesity, diabetes, and the combination of obesity plus diabetes (1,4,18,43,59,159,162,218,219,377,393-395). Impaired glycogen synthesis also represents the major cause of insulin resistance in obese subjects with normal or only slightly impaired glucose tolerance (1,4,162,218,393,395,396). Thus, the inability of insulin to promote glycogen synthesis is a characteristic and early defect in the development of insulin resistance in both obesity and type 2 diabetes. The emergence of overt diabetes with fasting hyperglycemia is associated with a major reduction in insulin-mediated nonoxidative glucose disposal (glycogen synthesis) in all ethnic groups (1,4,18,162,377,396). Impaired glycogen synthesis also has been demonstrated in the normal-glucose-tolerant offspring of two diabetic parents (43,397), in the first-degree relatives of type 2 diabetic individuals (41,398,399), and in the normoglycemic twin of a monozygotic twin pair in which the other twin has type 2 diabetes (101).

Using NMR imaging spectroscopy, a decrease in insulin-stimulated incorporation of [1H, 13C]-glucose into muscle glycogen of type 2 diabetic subjects has been demonstrated directly (215) . In type 2 diabetics, there was a marked lag in the onset of insulin-stimulated glycogen synthesis , that was similar to the delay in insulin-mediated leg muscle glucose uptake . The rate of glycogen synthesis in type 2 diabetic subjects was decreased by ~50%, paralleling the decrease in total glucose uptake by leg muscle (3) , and impaired muscle glycogen synthesis accounted for essentially all of the defect in whole body glucose disposal.

In summary, an abundance of convincing evidence demonstrates that impaired glycogen synthesis is the major metabolic defect in normal glucose tolerant obese subjects, in individuals with IGT, and in patients with overt diabetes. Moreover, numerous studies have documented that the earliest detectable metabolic abnormality responsible for the insulin resistance in normal glucose tolerant individuals who are destined to develop type 2 diabetes is impaired glycogen synthesis (4,41,43,101,382,392,399,400).

Glycogen synthase is the key insulin-regulated enzyme which controls the rate of muscle glycogen synthesis (307,308,310,379,401,402). Insulin enhances glycogen synthase activity by stimulating a cascade of phosphorylation dephosphorylation reactions (307,308,361-363,403) (see above discussion of insulin receptor signal transduction), which ultimately lead to the activation of PP1 (also called glycogen synthase phosphatase) (307,308,310,402). The regulatory subunit (G) of PP1 has two serine phosphorylation sites, called site 1 and site 2. Phosphorylation of site 2 by cAMP-dependent kinase (PKA) inactivates PP1, while phosphorylation of site 1 by insulin activates PP1, leading to the stimulation of glycogen synthase (307,308,402,404). Phosphorylation of site 1 of PP1 by insulin in muscle is catalyzed by insulin-stimulated protein kinase 1 (ISPK-1) (309,405), which is part of a family of serine/threonine protein kinases termed ribosomal S6-kinases. Because of their central role in muscle glycogen formation, considerable attention has focused on the three enzymes glycogen synthase, PP1, and ISPK-1 in the pathogenesis of insulin resistance in individuals with type 2 diabetes.

Glycogen synthase exists in an active (dephosphorylated) and an inactive (phosphorylated) form (307-310). Under fasting conditions, total glycogen synthase activity in type 2 diabetic subjects is reduced and the ability of insulin to activate glycogen synthase is severely impaired (301,384,406-410). An impaired ability of insulin to activate glycogen synthase also has been demonstrated in the normal glucose tolerant relatives of type 2 diabetic individuals (400). Insulin-mediated activation of glycogen synthase and insulin-stimulated glycogen synthase gene expression have been shown to be impaired in cultured myocytes and fibroblasts from type 2 diabetic subjects (411,412). Studies in insulin-resistant nondiabetic and diabetic Pima Indians have documented that the ability of insulin to activate muscle PP1 (glycogen synthase phosphatase) is severely reduced (413). PP1 dephosphorylates glycogen synthase, leading to its activation. Therefore, a defect in PP1 appears to play an important role in muscle insulin resistance (309).

The effect of insulin on glycogen synthase gene transcription and translation in vivo has been studied extensively. Most studies (378,414,415) have shown that insulin does not increase glycogen synthase mRNA or protein expression in human muscle studied in vivo. However, glycogen synthase mRNA expression is decreased in muscle of type 2 diabetic patients (415,416), explaining in part the decreased glycogen synthase activity in this disease. However, the major abnormality in glycogen synthase regulation in type 2 diabetes and other insulin resistant conditions is its lack of dephosphorylation and activation by insulin as a result of insulin receptor signaling abnormalities (see previous discussion). The glycogen synthase gene (417) has been the subject of intensive investigation. An association between glycogen synthase gene markers and type 2 diabetes has been demonstrated in Japanese, French, Finnish, and Pima Indian populations. However, DNA sequencing has revealed either no mutations (418) or rare nucleotide substitutions (419,420) that cannot explain the defect in insulin-stimulated glycogen synthase. Nonetheless, the association between the glycogen synthase gene and type 2 diabetes mellitus (418) suggests that another gene close to the glycogen synthase gene may be involved in the development of type 2 diabetes. The genes encoding the catalytic subunits of PP1 (421) and ISPK-1 (422) have been examined in insulin-resistant Pima Indians and Danes with type 2 diabetes. Several silent nucleotide substitutions were found in the PP1 and ISPK-1 genes in the Danish population; the mRNA levels of both genes were normal in skeletal muscle (422). No structural gene abnormalities in the catalytic subunit of PP1 were detected in Pima Indians (422). Thus, neither abnormalities in the PP1 and ISPK-1 genes nor abnormalities in their translation can explain the impaired enzymatic activities of glycogen synthase and PP1 that have been observed in vivo. Similarly, there is no evidence that an alteration in glycogen phosphorylase plays any role in the abnormality in glycogen formation in type 2 diabetes (423).

In summary, glycogen synthase activity is severely impaired in patients with type 2 diabetes mellitus and in insulin-resistant normal glucose tolerant individuals who are predisposed to develop type 2 diabetes. However, the defect cannot be explained by an abnormality in the genes encoding glycogen synthase or is promoter or by other key genes - PP1 or ISPK-1 - involved in the regulation of glycogen synthase activity.




Glycolysis/Glucose Oxidation

Glucose oxidation accounts for ~90% of total glycolytic flux, while anaerobic glycolysis accounts for the other 10% (393,394). Two enzymes, phosphofructokinase (PFK) and pyruvate dehydrogenase (PDH), play pivotal roles in the regulation of glycolysis and glucose oxidation, respectively. In type 2 diabetic individuals the glycolytic/glucose oxidative pathway has been show to be impaired in many individuals with type 2 diabetes (393,394). Although one study suggested that the activity of PFK is modestly reduced in muscle biopsies from type 2 diabetic subjects (424), the majority of evidence indicates that the activity of PFK is normal (407,412,417). Insulin has no effect on muscle PFK activity, mRNA levels, or protein content in either nondiabetic or diabetic individuals (417). PDH is a key insulin-regulated enzyme whose activity in muscle is acutely stimulated by a physiological increment in the plasma insulin concentration (415). Three previous studies have examined PDH activity in type 2 diabetic patients. Insulin-stimulated PDH activity is decreased in isolated subcutaneous human adipocytes from patients with type 2 diabetes mellitus (425) and in skeletal muscle from type 2 diabetic subjects undergoing euglycemic hyperinsulinemic clamps (426). However, when type 2 diabetic patients had muscle biopsies during hyperglycemic hyperinsulinemic clamps, activation of PDH by insulin was normal (409), in concert with normalized rates of muscle glucose uptake. These results suggest that insulin stimulation of PDH activity is influenced by glycolytic flux.


Both obesity and type 2 diabetes mellitus are associated with accelerated FFA turnover and oxidation (1,4,18,162), which would be expected, according to the Randle cycle (232), to inhibit PDH activity and consequently glucose oxidation (see prior discussion). Thus, any observed defect in glucose oxidation or PDH activity could be acquired secondarily to increased FFA oxidation and feedback inhibition of PDH by elevated intracellular levels of acetyl-CoA and reduced availability of NAD. Consistent with this observation, the rates of basal and insulin-stimulated glucose oxidation have been shown to be normal in the normal glucose tolerant offspring of two diabetic parents (43) and in the first degree relatives of type 2 diabetic subjects (41,423), while it is decreased in overtly diabetic subjects (1,4,393,394,427). Studies examining PHD activity in muscle tissue from lean diabetic subjects with mild fasting hyperglycemia are needed before the role of this enzyme in the development of insulin resistance in type 2 diabetes can be established or excluded.


In summary, postbinding defects in insulin action primarily are responsible for the insulin resistance in type 2 diabetes. Diminished insulin binding, when present, is small, occurs in individuals with IGT or very mild diabetes, and results secondarily from downregulation of the insulin receptor by chronic sustained hyperinsulinemia. In type 2 diabetic patients with overt fasting hyperglycemia, postbinding defects are responsible for the insulin resistance. A number of postbinding defects have been documented, including diminished insulin receptor tyrosine kinase activity, insulin signal transduction abnormalities, decreased glucose transport, reduced glucose phosphorylation, and impaired glycogen synthase activity. The glycolytic/glucose oxidative pathway appears to be largely intact and, when defects are observed, they appear to be acquired secondarily to enhanced FFA/lipid oxidation. From the quantitative standpoint, impaired glycogen synthesis represents the major pathway responsible for the insulin resistance in type 2 diabetes, and family studies suggests that a defect in the glycogen synthetic pathway represents the earliest detectable abnormality in type 2 diabetes. Recent studies link the impairment in glycogen synthase activation to a defect in the ability of insulin to phosphorylate IRS-1, causing a reduced association of the p85 subunit of PI 3-kinase with IRS-1 and decreased activation of the enzyme (PI 3-kinase).




1. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus: metabolic and molecular implications for identifying diabetes genes. Diabetes 5:117-269, 1997.

2. Grill V. A comparison of brain glucose metabolism in diabetes as measured by positron emission tomography or by arteriovenous techniques. Ann Med 22:171-175, 1990.

3. DeFronzo RA, Gunnarsson R, Bjorkman O, Olsson M, Wahren J. Effects of insulin on peripheral and splanchnic glucose metabolism in non-insulin dependent diabetes mellitus. J. Clin Invest 76: 149-155, 1985.

4. DeFronzo RA. Lilly Lecture. The triumvirate: beta cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37: 667-687, 1988.

5. DeFronzo RA, Jacot E, Jequier E, Maeder E, Wahren J, Felber JP. The effect of insulin on the disposal of intravenous glucose: results from indirect calorimetry. Diabetes 30:1000-1007, 1981.

6. DeFronzo RA, Ferrannini E. Regulation of hepatic glucose metabolism in humans. Diabetes Metab Rev 3:415-459, 1987.

7. Mari A, Wahren J, DeFronzo RA, Ferrannini E. Glucose absorption and production following oral glucose: comparison of compartmental and arteriovenous-difference methods. Metabolism 43:1419-1425, 1994.

8. Gerich JE, Meyer C, Woerle HJ, Stumvoll M. Renal gluconeogenesis. Its importance in human glucose homeostasis. Diabetes Care 24:382-391, 2001.

9. Ekberg K, Landau BR, Wajngot A, Chandramouli V, Efendic S, Brunengraber H, Wahren J. Contributions by kidney and liver to glucose production in the postabsorptive state and after 60 h of fasting. Diabetes 48:292-298, 1999.

10. Magnusson I. Katz LD. Shulman RG. Shulman GI. Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR. Science. 254:573-6, 1991

11. Katz LD, Glickman MG, Rapoport S, Ferrannini E, DeFronzo RA. Splanchnic and peripheral disposal of oral glucose in man. Diabetes 32:675-679, 1983.

12. Ferrannini E, Bjorkman O, Reichard GA Jr, Pilo A, Olsson M, Wahren J, DeFronzo RA. The disposal of an oral glucose load in healthy subjects. Diabetes 34:580-588, 1985.

13. Mitrakou A, Kelley D, Veneman T, Jensen T, Pangburn T, Reilly J, Gerich J. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes 39:1381-90, 1990.

14. Mandarino L, Bonadonna R, McGuinness O, Wasserman D. Regulation of Muscle Glucose Uptake In Vivo. In: Handbook of Physiology, Section 7, The Endocrine System, Vol. II, The Endocrine Pancreas and Regulation of Metabolism, pp 803-848, L.S. Jefferson and A.D. Cherrington, eds., Oxford University Press, 2001.

15. Del Prato S. Riccio A. Vigili de Kreutzenberg S. Dorella M. Tiengo A. DeFronzo RA. Basal plasma insulin levels exert a qualitative but not quantitative effect on glucose-mediated glucose uptake. Am J Physiol 268:E1089-95, 1995.

16. Cherrington AD. Control of glucose uptake and release by the liver in vivo. Diabetes 48:1198-1214, 1999.

17. Jansson P-A, Larsson A, Smith U, Lonroth P. Lactate release from the subcutaneous tissue in lean and obese men. J Clin Invest 93:240-246, 1994.

18. Groop LC, Bonadonna RC, Del Prato S Ratheiser K, Zych K, Ferrannini E, DeFronzo RA. Glucose and free fatty acid metabolism in non-insulin dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 84:205-215, 1989

19. Santomauro A, Boden G, Silva M, Rocha DM, Santos RF, Ursich MJM, Strassman PG, Wajchenberg BL. Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and non-diabetic subjects. Diabetes 48:1836-1841, 1999.

20. Bergman RN. Non-esterified fatty acids and the liver: why is insulin secreted into the portal vein?. Diabetologia. 43:946-52, 2000.

21. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3-10, 1997.

22. McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes. 51:7-18, 2002.

23. Baron AD. Schaeffer L. Shragg P. Kolterman OG. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes. 36:274-83, 1987.

24. DeFronzo RA, Ferrannini E, Hendler R, Wahren J, and Felig P. Influence of hyperinsulinemia, hyperglycemia, and the route of glucose administration on splanchnic glucose exchange. Proc Natl Acad Sci 75:5173-5177, 1978.

25. Ferrannini E, Wahren J, Felig P, DeFronzo RA. Role of fractional glucose extraction in the regulation of splanchnic glucose metabolism in normal and diabetic man. Metabolism 29:28-35, 1980.

26. Hsieh P-S, Moore MC, Neal DW, Cherrington AD. Hepatic glucose uptake rapidly decreases after removal of the portal signal in conscious dogs. Am J Physiol 275:E987-E992, 1998.

27. Adkins-Marshall B, Pagliassotti MJ, Asher JR, Connolly CC, Neal DW, Williams PE, Myers SR, Hendrick GK, Adkins RB Jr, Cherrington AD. Role of hepatic nerves in response of liver to intraportal delivery in dogs. Am J Physiol 262:E679-E686, 1992.

28. Creutzfeldt W. The incretin concept today. Diabetologia 16:75-85, 1979.

29. Drucker DJ. Glucagon-like peptides. Diabetes 47:159-169, 1998.

30. Holst JJ, Gromada J, Nauck MA. The pathogenesis of NIDDM involves a defective expression of the GIP receptor. Diabetologia 40:984-986, 1997.

31. Polonsky KS, Sturis J, Bell GI. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 334:777-783, 1996.

32. Cerasi E. Insulin deficiency and insulin resistance in the pathogenesis of NIDDM: is a divorce possible? Diabetologia 38:992-997, 1995.

33. Sicree RA, Zimmet P, King HO, Coventry JO. Plasma insulin response among Nauruans. Prediction of deterioration in glucose tolerance over 6 years. Diabetes 36:179-186, 1987.

34. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH. Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes. Lancet i:1356-1359, 1989.

35. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH. The natural history of impaired glucose tolerance in the Pima Indians. New Engl J Med 319:1500-1505, 1988.

36. Haffner SM, Miettinen H, Gaskill SP, Stern MP. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans. Diabetes 44:1386-1391, 1995.

37. Weyer C, Hanson RL, Tataranni PA, Bogardus C, Pratley RE. A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance. Evidence for a pathogenic role of relative hyperinsulinemia. Diabetes 49:2094-2101, 2000.

38. Weyer C, Bogardus C, Pratley RE. Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 48:2197-2203, 1999.

39. Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 24:89-94, 2000.

40. Pimenta W, Korytkowski M, Mitrakou A, Jenssen T, Yki-Jarvinen H, Evron W, Dailey G, Gerich J. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first degree NIDDM relative. JAMA 273:1855-1861, 1995.

41. Eriksson J, Franssila-Kallunki A, Ekstrand A, Saloranta C, Widen E, Schalin C, Groop L. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. New Engl J Med 321:337-343, 1989.

42. Reaven GM, Hollenbeck CB, Chen YDI. Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance. Diabetologia 32:52-55, 1989.

43. Gulli G, Ferrannini E, Stern M, Haffner S, DeFronzo RA. The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents. Diabetes 41:1575-1586, 1992.

44. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn RC. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 340:925-929, 1992.

45. Lillioja S, Mott DM, Zawadzki JK, Young AA, Abbott WG, Knowler WC, Bennett PH, Moll P, Bogardus C. In vivo insulin action is familial characteristic in nondiabetic Pima Indians. Diabetes 36:1329-1335, 1987.

46. Kahn SE. Clinical Review 135. The importance of ß-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 86:4047-4058, 2001.

47. Bergman RN, Finegood DT, Kahn SE. The evolution of ß-cell dysfunction and insulin resistance in type 2 diabetes. European J Clin Invest 32:35-45, 2002.

48. Hansen BC, Bodkin NH. Heterogeneity of insulin responses: phases leading to type 2 (noninsulin-dependent) diabetes mellitus in the rhesus monkey. Diabetologia 29:713-719, 1986.

49. Diamond MP, Thornton K, Connolly-Diamond M, Sherwin RS, DeFronzo RA. Reciprocal variations in insulin-stimulated glucose uptake and pancreatic insulin secretion in women with normal glucose tolerance. J Soc Gynecol Invest 2:708-715, 1995.

50. Hollenbeck CB, Reaven GM. Variations in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance. J Clin Endocrinol Metab 64:1169-1173, 1987.

51. Reaven GM. Banting Lecture. Role of insulin resistance in human disease. Diabetes 37:595-607, 1988.

52. Faber OK, Damsgaard EM. Insulin secretion in type II diabetes. Acta Endocrinol 262 (suppl.):47-50, 1984.

53. Faber OK, Hagen C, Binder C, Markussen J, Naithani VK, Blix PM, Kuzuya H, Horwitz DL, Rubenstein AH, Rossing N. Kinetics of human connecting peptide in normal and diabetic subjects. J Clin Invest 62: 197-203, 1978.

54. DeFronzo RA, Ferrannini E, Simonson DC. J Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 38: 387-95, 1989.

55. Hales CN. The pathogenesis of NIDDM. Diabetologia 37:S162-S168, 1994.

56. Reaven GM, Hollenbeck C, Jeng C-Y, Wu MS, Chen Y-DI. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 hours in patients with NIDDM. Diabetes 37: 1020-4, 1988.

57. Garvey WT, Olefsky JM, Rubenstein AH, Kolterman OG. Day-long integrated urinary C-peptide excretion. Diabetes 37: 590-9, 1988.

58. Lillioja S, Mott DM, Howard BV,Bennett PH, Yki-Jarvinen H, Freymond D, Nyomba BL, Zurlo F, Swinburn B, Bogardus C. Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. New Engl J Med 318: 1217-25, 1988.

59. Jallut D, Golay A, Munger R, Frascarolo P, Schutz Y, Jequier E, Felber JP. Impaired glucose tolerance and diabetes in obesity: a 6 year follow-up study of glucose metabolism. Metabolism 39:1068-1075, 1990.

60. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, Knowler WC, Bennett PH, Bogardus C. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. N Engl J Med 329:1988-1992, 1993.

61. Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE, the American Diabetes Association GENNID Study Group. ß-cell function is a major contributor to oral glucose tolerance in high-risk relatives of our ethnic groups in the U.S. Diabetes 51:2170-2178, 2002.

62. Dowse GK, Zimmet PZ, Collins VR. Insulin levels and the natural history of glucose intolerance in Nauruans. Diabetes 45:1367-1372, 1996.

63. Haffner SM, Stern MP, Hazuda HP, Pugh JA, Patterson JK. Hyperinsulinemia in a population at high risk for non-insulin-dependent diabetes mellitus. New Engl J Med 315: 220-4, 1986.

64. Ho LT, Chang ZY, Wang JT, Li SH, Liu YF, Chen Y-DI, Reaven GM. Insulin insensitivity in offspring of parents with type 2 diabetes mellitus. Diabet Med 7: 31-34, 1990.

65. Clement K, Pueyo ME, Vaxillaire M, Rakotoambinina B, Thuillier F, Passa PH, Froguel PH, Robert JJ, Velho G. Assessment of insulin sensitivity in glucokinase-deficient subjects. Diabetologia 39:82-90, 1996.

66. Polonsky KS. Lilly Lecture 1994. The beta cell in diabetes: from molecular genetics to clinical research. Diabetes 44:705-717, 1995.

67. Bell GI, Polonsky KS. Diabetes mellitus and genetically programmed defects in ß-cell function. Nature 414:788-791, 2001.

68. McCarthy MI, Froguel P. Genetic approaches to the molecular understanding of type 2 diabetes. Am J Physiol 283:E217-E225, 2002.

69. Bell GI, Zian K, Newman M, Wu S, Wright L, Fajans S., Spielman RS, Cox NJ. Gene for non-insulin-dependent diabetes mellitus (maturity-onset diabetes of the young subtype) is linked to DNA polymorphism on human chromosome 20q. Proc. Natl. Acad. Sci. 88:1484-1488, 1991.

70. Froguel PH, Zouali H, Vionnet N, Velho G, Vaxillaire M, Sun F, Lesage S, Stoffel M, Takeda J, Passap P. Familial hyperglycaemia due to mutations in glucokinase: definition of a subtype of diabetes mellitus. N Engl J Med 328:697-702, 1993.

71. Menzel S, Yamagata K, Trabb JB, Nerup J, Permutt MA, Fajans SS, Menzel R, Iwasaki N, Omori Y, Cox N, Bell GI. Localization of MODY3 to a 5-cM Region of Human Chromosome 12. Diabetes 44:1408-1413, 1995.

72. Zhang Y, Warren-Perry M, Saker PJ, Hattersley AT, Mackie ADR, Baird JD, Greenwood RH, Stoffel M, Bell GI, Turner RC. Candidate gene studies in pedigrees with maturity-onset diabetes of the young not lined with glucokinase. Diabetologia 38:1055-1066, 1995.

73. Weng J, Macfarlane WM, Lehto M, Gu HF, Shepherd LM, Ivarsson SA, Wibell L, Smith T, Groop LC. Functional consequences of mutations in the MODY4 gene (IPF1) and coexistence with MODY3 mutations. Diabetologia 44:249-258, 2001.

74. Sturis J, Kurland IJ, Byrne MM, Mosekilde E, Froguel P, Pilkis SJ, Bell GI, Polonsky KS. Compensation in pancreatic ß-cell function in subjects with glucokinase mutations. Diabetes 43:718-723, 1994.

75. Beck-Nielsen H, Nielsen OH, Pedersen O, Bak J, Faber O, Schmitz O. Insulin action and insulin secretion in identical twins with MODY: evidence for defects in both insulin action and insulin secretion. Diabetes 37:730-735, 1988.

76. Mohan V, Sharp PS, Aber VR, Mather HM, Kohner EM. Insulin resistance in maturity-onset diabetes of the young. Diabetes Metab 13:193-197, 1988.

77. Elbein SC, Hoffman M, Qin H, Chiu K, Tanizawa Y, Permutt MA. Molecular screening of the glucokinase gene in familial type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia37:182-187, 1994.

78. Efendic S, Grill V, Luft R, Wajngot A. Low insulin response: a marker of pre-diabetes. Adv Exp Med Biol 246:167-174, 1988.

79. Davies MJ, Metcalfe J, Gray IP, Day JL, Hales CN. Insulin deficiency rather than hyperinsulinaemia in newly diagnosed type 2 diabetes mellitus. Diabetic Med 10:305-312, 1993.

80. Chen K-W, Boyko EJ, Bergstrom RW, Leonetti DL, Newell-Morris L, Wahl PW, Fujimoto WY. Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM. 5-year follow-up of initially nondiabetic Japanese-American men. Diabetes Care 18:747-753, 1995.

81. Arner P, Pollare T, Lithell H. Different etiologies of Type 2 (non-insulin-dependent) diabetes mellitus in obese and non-obese subjects. Diabetologia 34:483-487, 1991.

82. Ferrannini E. Natali A. Bell P. Cavallo-Perin P. Lalic N. Mingrone G. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). [Journal Article] Journal of Clinical Investigation. 100(5):1166-73, 1997

83. Banjeri MA, Lebovitz HE. Insulin action in black Americans with NIDDM. Diates Care 15:1295-1302, 1992.

84. Mbanya J-CN, Pani LN, Mbanya DNS, Sobngwi E, Ngogang J. Reduced insulin secretion in offspring of African type 2 diabetic patients. Diabetes Care 23:1761-1765, 2000.

85. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 6: E214-23, 1979.

86. Curry DL, Bennett LL, Grodsky GM. Dynamics of insulin secretion by the perfused rat pancreas. Endocrinology 83: 572-584, 1968.

87. Temple R, Clark PMS, Hales CN. Measurement of insulin secretion in type 2 diabetes: problems and pitfalls. Diab Med 9:503-512, 1992.

88. Brunzell JD, Robertson RP, Lerner RL, Hazzard WR, Ensinck JW, Bierman EL, Porte D. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol 46: 222-229, 1976.

89. Vague P, Moulin J-P. The defective glucose sensitivity of the B cell in insulin dependent diabetes. Improvement after twenty hours of normoglycaemia. Metabolism 31: 139-142, 1982.

90. Kosaka K, Kuzuya T, Akanuma Y, Hagura R. Increase in insulin response after treatment of overt maturity onset diabetes mellitus is independent of the mode of treatment. Diabetologia 18: 23-28, 1980.

91. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care 13:610-630, 1990.

92. Prentki M, Corkey BE. Are the beta cell signaling molecules malonyl-CoA and cytosolic long-chain acyl-CoA implicated in multiple tissue defects of obesity and NIDDM? Diabetes 45:273-283, 1996.

93. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 44:863-870, 1995.

94. Shimabukuro M, Zhou Y-T, Levi M, Unger RH. Fatty acid induced ß cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci 95:2498-2502, 1998.

95. Bruce DG, Chisholm DJ, Storlien LH, Kraegen EW. Physiological importance of deficiency in early prandial insulin secretion in non-insulin dependent diabetes. Diabetes 37: 736-744, 1988.

96. Luzi L. Effect of the loss of first phase insulin secretion on glucose production and disposal in man. Am J Physiol 257: E241-E246, 1989.

97. Bonner-Weir S. ß-cell turnover. Its assessment and implications. Diabetes 50:S20-S24, 2001.

98. Haffner SM, Miettinen H, Stern MP. Insulin secretion and resistance in nondiabetic Mexican Americans and non-Hispanic whites with a parental history of diabetes. J Clin Endocrinol Metab 81:1846-1851, 1996.

99. Gautier J-F, Wilson C, Weyer C, Mott D, Knowler WC, Cavaghan M, Polonsky KS, Bogardus C, Pratley RE. Low acute insulin secretory responses in adult offspring of people with early onset type 2 diabetes. Diabetes 50:1828-1833, 2001.

100. Vauhkonen N, Niskanen L, Vanninen E, Kainulainen S, Uusitupa M, Laakso M. Defects in insulin secretion and insulin action in non-insulin-dependent diabetes mellitus are inherited. Metabolic studies on offspring of diabetic probands. J Clin Invest 100:86-96, 1997.

101. Vaag A, Henriksen JE, Madsbad S, Holm N, Beck-Nielsen H. Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus. J Clin Invest 95:690-698, 1995.

102. Barnett AH, Spilipoulos AJ, Pyke DA, Stubbs WA, Burrin J, Alberti KGMM. Metabolic studies in unaffected co-twins of non-insulin-dependent diabetics. Brit Med J 282:1656-1658, 1981.

103. Watanabe RM. Valle T. Hauser ER. Ghosh S. Eriksson J. Kohtamaki K. Ehnholm C. Tuomilehto J. Collins FS. Bergman RN. Boehnke M. Familiality of quantitative metabolic traits in Finnish families with non-insulin-dependent diabetes mellitus. Finland-United States Investigation of NIDDM Genetics (FUSION) Study investigators. Human Heredity. 49(3):159-68, 1999.

104. Mahtani MM. Widen E. Lehto M. Thomas J. McCarthy M. Brayer J. Bryant B. Chan G. Daly M. Forsblom C. Kanninen T. Kirby A. Kruglyak L. Munnelly K. Parkkonen M. Reeve-Daly MP. Weaver A. Brettin T. Duyk G. Lander ES. Groop LC. Mapping of a gene for type 2 diabetes associated with an insulin secretion defect by a genome scan in Finnish families. Nature Genetics. 14:90-4, 1996.

105. Rossetti L, Shulman Gi, Zawalich W, DeFronzo RA. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 80:1037-1044, 1987.

106. Leahy JL, Bonner-Weir S, Weir GC. Abnormal glucose regulation of insulin secretion in models of reduced beta-cell mass. Diabetes 33: 667-73, 1984.

107. Leahy JL, Bonner-Weir S, Weir GC. Minimal chronic hyperglycemia is a critical determinant of impaired insulin secretion after an incomplete pancreatectomy. J Clin Invest 81: 1407-14, 1988.

108. Leahy JL, Cooper HE, Weir GC. Impaired insulin secretion associated with near normoglycemia. Diabetes 36: 459-464, 1987.

109. Robertson RP, Olson IK, Zhang H-J. Differentiating glucose toxicity from glucose desensitization: a new message from the insulin gene. Diabetes 43:1085-1089, 1994.

110. Newgard CB, McGarry JD. Metabolic coupling factors in pancreatic beta cell signal transduction. Annu Rev Biochem 64:689-719, 1995.

111. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258:607-614, 1992.

112. Zhou YP, Grill VE. Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest 93:870-876,1994.

113. Shimabukuro M. Higa M. Zhou YT. Wang MY. Newgard CB. Unger RH. Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats. Role of serine palmitoyltransferase overexpression. J Biol Chem. 273:32487-90, 1998.

114. Fehmann HC. Goke R. Goke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocrine Reviews. 16:390-410, 1995.

115. Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology. 142:521-527, 2001

116. Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W: Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76:912-917, 1993

117. D'Alessio DA. Vogel R. Prigeon R. Laschansky E. Koerker D. Eng J. Ensinck JW. Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J Clin Invest 97:133-138, 1996.

118. Schirra J. Sturm K. Leicht P. Arnold R. Goke B. Katschinski M. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J Clin Invest 101:1421-30, 1998

119. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 Amide] but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus. J Clin Invest 91:301-307, 1993.

120. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50:609-613, 2001.

121. Ahren B, Larsson H, Holst JJ. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:473-478, 1997.

122. Nanauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744, 1993.

123. Xu G. Stoffers DA. Habener JF. Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 48:2270-2276, 1999.

124. Kahn SE, Andrikopoulos S, Verchere CB. Islet amyloid. A long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 48:241-253, 1999.

125. Johnson KH, O'Brien TD, Betysholtz C, Westermark P. Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus. New Engl J Med 321: 513-518, 1989.

126. Ohsawa H, Kanatsuka A, Yamaguchi T, Makino H, Yoshida S. Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic islets. Biochem Biophys Res Comm 160: 961-967, 1989.

127. Howard CF. Longitudinal studies on the development of diabetes in individual macaca nigra. Diabetologia 29: 301-306, 1986.

128. Hartter E, Svoboda T, Ludvik B, Schuller M, Lell B, Kuenburg E, Brunnbauer M, Woloszczuk W, Prager R. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia 34:52-54, 1991.

129. Eriksson J, Nakazato M, Miyazato M, Shiomi K, Matsukura S, Groop L. Islet amyloid polypeptide: plasma-concentrations in individuals at increased risk of developing type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 35:292-293, 1992.

130. Westermark GT, Christmanson L, Terenghi G, Permerth J, Betsoltz C, Larsson J, Polak JM, Westermark P. Islet amyloid polypeptide: demonstration of mRNA in human pancreatic islets by in situ hybridization in islets with and without amyloid deposits. Diabetologia 36:323-328,1993.

131. Ghatei MA, Datta HK, Zaidi M, BrethertonWatt D, Wimalawansa SJ, Maclntyre 1, Bloom SR. Amylin and amylin-amide lack an acute effect on blood glucose and insulin. J. Endocrinol 124: R9-R11, 1990.

132. Bretherton-Watt D, Gilbey SG, Ghatei MA, Beacham J, Bloom SR. Failure to establish islet amyloid polypeptide (amylin) as a circulating beta cell inhibiting hormone in man. Diabetologia 33: 115-117, 1990.

133. Hoppener JWM, Verbeek JS, de Koning EJP, Oosterwijk C, van Hulst KL, Visser-Vernooy HJ, Hofhuis FMA, van Gaalen S, Berends MJH, Hackeng WHL, Jansz HS, Morris JF, Clark A, Capel PJA, Lipis CJM. Chronic overproduction of islet amyloid polypeptide-amylin in transgenic mice: lysosomal localization of human islet amyloid polypeptide and lack of marked hyperglycaemia or hyperinsulinaemia. Diabetologia 36:1258-1265, 1993.

134. Gebre-Medhin S, Olofsson C, Mulder H. Islet amyloid polypeptide in the islets of Langerhans: friend or foe? Diabetologia 43:687-695, 2000.

135. Westermark P, Wilander E. The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia 15: 417-421, 1978.

136. Gepts W, Lecompte PM. The pancreatic islets in diabetes. Am J Med 70: 105-114, 1981.

137. Kloppel G, Lohr M, Habich K, Oberholzer M, Heitz PU. Islet pathology and the pathogenesis of type I and type 2 diabetes mellitus revisited. Surv Synth Path Res 4: 110-25, 1985.

138. Clark A, Wells CA, Buley ID , Cruickshank JK, Vanhegan RI, Matthews DR, Cooper GJ, Holman RR, Turner RC. Islet amyloid, increased alpha-cells, reduced beta-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res 9: 151-159, 1988.

139 Butler AE, Janson J, Bonner-Weir S, Ritzel RA, Butler PC. Decreased ?-cell mass inpatients with type-2 diabetes mellitus. Diabetes 51(suppl 2):A367, 2002.

140. Stefan Y, Orci L, Malaisse-Lagae F, Perrelet A, Patel Y, Unger R. Quantitation of endocrine cell content in the pancreas of non-diabetic and diabetic humans. Diabetes 31: 694-700, 1982.

141. Rahier J, Sempoux C, Moulin P, Guiot Y. No decrease of the B cell mass in type 2 diabetic patients. Diabetologia 43(Suppl 1):A65, 2000.

142. Janson J, Butler AE, Bonner-Weir S, Ritzel RA, Sultana C, Butler PC. Failure of compensatory increase in new islet formation in humans with type-2 diabetes mellitus. Diabetes 51(suppl 2): A377, 2002.

143. Hales CN, Barker DJP, Clark PM, Cox J, Fall C, Osmond C, Winter PD. Fetal and infant growth and impaired glucose tolerance at age 64 years. BMJ 303:1019-1022, 1991.

144. Eriksson UJ. Lifelong consequences of metabolic adaptations in utero? Diabetologia 39:1123-1125, 1996.

145. Hales CN, Barker DJP. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia 35:595-601, 1993.

146. Phillips DIW. Insulin resistance as a programmed response to fetal under nutrition. Diabetologia 39:1119-1122, 1996.

147. Strauss W, Hales C. Plasma insulin in minor abnormalities of glucose tolerance: a 5 year follow-up. Diabetologia 10:237-243, 1974.

148. Hara H, Egusa G Yamakido M, Kawate R. The high prevalence of diabetes mellitus and hyperinsulinemia among the Japanese-Americans living in Hawaii and Los Angeles. Diabetes Res Clin Pract 24:(Suppl. 1):S37-S42, 1994.

149. Berrish TS, Hetherington CS, Alberti KGMM, Walker M. Peripheral and hepatic insulin sensitivity in subjects with impaired glucose tolerance. Diabetologia 38:699-704, 1995.

150. Lillioja S, Nyomba BL, Saad MF, Ferraro R, Castillo C, Bennett PH, Bogardus C. Exaggerated early insulin release and insulin resistance in a diabetes-prone population: a metabolic comparison of Pima Indians and Caucasians. J Clin Endocrinol Metab 73:866-876, 1991.

151. Himsworth HP, Kerr RB. Insulin-sensitive and insulin-insensitive types of diabetes mellitus. Clin Sci 4: 120-152, 1939.

152. Ginsberg H, Kimmerling G, Olefsky JM, Reaven GM. Demonstration of insulin resistance in untreated adult-onset diabetic subjects with fasting hyperglycemia. J Clin Invest 55: 454-461, 1975.

153. Butterfield WJH, Whichelow MJ. Peripheral glucose metabolism in control subjects and diabetic patients during glucose, glucose-insulin, and insulin sensitivity tests. Diabetologia 1:43-53, 1965.

154. Katz H, Homan M, Jensen M, Caumo A, Cobelli C, Rizza R. Assessment of insulin action in NIDDM in the presence of dynamic changes in insulin and glucose concentration. Diabetes 43:289-296, 1994.

155. Wangot A, Roovete A, Vranic M. Luft R, Efendic S. Insulin resistance and decreased insulin response to glucose in lean type II diabetes. Proc Natl Acad Sci USA 79:4432-4437, 1982.

156. Bergman RN. Lilly Lecture. Toward physiological understanding of glucose tolerance- minimal-model approach. Diabetes 38:1512-26, 1989.

157. DeFronzo RA, Deibert D, Hendler R, Felig P. Insulin sensitivity and insulin binding to monocytes in maturity-onset diabetes. J Clin Invest 63: 939-946, 1982.

158. DeFronzo RA, Simonson D, Ferrannini E. Hepatic and peripheral insulin resistance: a common feature in non-insulin-dependent and insulin-dependent diabetes. Diabetologia 23: 313-319, 1982.

159. Golay A, DeFronzo RA, Ferrannini E, Simonson DC, Thorin D, Acheson K, Thiebaud D, Curchod B, Jequier E, Felber JP. Oxidative and non-oxidative glucose metabolism in non-obese Type 2 (non-insulin dependent) diabetic patients. Diabetologia 31:585-591, 1988.

160. Dall'Aglio E, Chang H, Hollenbeck CB, Mondon CE, Sims C, Reaven GM. In vivo and in vitro resistance to maximal insulin-stimulated glucose disposal in insulin deficiency. Am J Physiol 249: E312-E316, 1985.

161. Vuorinen-Markkola H, Koivisto VA, Yki-Järvinen H: Mechanisms of hyperglycemia-induced insulin resistance in whole body and skeletal muscle of type 1 diabetic patients. Diabetes 41:571-580, 1992.

162. Golay A, Felber JP, Jequier E, DeFronzo RA, Ferrannini E. Metabolic basis of obesity and noninsulin-dependent diabetes mellitus. Diabetes Metab Rev 4:727-747, 1988.

163. DeFronzo RA, Sherwin RS, Hendler R, and Felig P. Insulin binding to monocytes and insulin action in human obesity, starvation, and refeeding. J Clin Invest 62:204-213, 1978.

164. Firth R, Bell P, Rizza R. Insulin action in non-insulin-dependent diabetes mellitus: the relationship between hepatic and extrahepatic insulin resistance and obesity. Metabolism 36:1091 -1095, 1987.

165. Campbell PJ, Mandarino LJ, Gerich JE. Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin dependent diabetes mellitus. Metabolism 37: 15-21, 1988.

166. Bogardus C, Lillioja S, Howard BV, Reaven G, Mott D. Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in non-diabetic and noninsulin-dependent subjects. J Clin Invest 74:1238-46, 1984.

167. Del Prato S, Simonson DC, Sheehan P, Cardi F, DeFronzo RA. Studies on the mass effect of glucose in diabetes. Evidence for glucose resistance. Diabetologia 40:687-697, 1997.

168. Nielsen MF, Basu R, Wise S, Caumo A, Cobelli C, Rizza RA. Normal glucose-induced suppression of glucose production but impaired stimulation of glucose disposal in type 2 diabetes. Evidence for a concentration-dependent defect in uptake. Diabetes 47:1735-1747, 1998.

169. Huang SC, Phelps ME, Hoffman EJ, Sideris K, Selin CJ, Kuhl DE. Non-invasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol 238:E69-E82, 1980.

170. Henry RR, Wallace P, Olefsky JM. Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin dependent diabetes mellitus. Diabetes 35: 990-998, 1986.

171. Best JD, Judzewitsch RG, Pfeiffer MA, Beard JC, Halter JB, Porte D. The effect of chronic sulfonylurea therapy on hepatic glucose production in non-insulin-dependent diabetes mellitus. Diabetes 31:333-338, 1982.

172. Tayek JA, Katz J. Glucose production, recycling, and gluconeogenesis in normals and diabetics: a mass isotopomer [U-13C] glucose study. Am J Physiol 270:E709-E717, 1996.

173. Fery F. Role of hepatic glucose production and glucose uptake in the pathogenesis of fasting hyperglycemia in Type 2 diabetes: normalization of glucose kinetics by short-term fasting. J Clin Endocrinol Metab 78:536-542, 1994.

174. Jeng C-Y, Sheu WHH, Fuh MM-T, Chen I, Reaven GM. Relationship between hepatic glucose production and fasting plasma glucose concentration in patients with NIDDM. Diabetes 43:1440-1444, 1994.

175. DeFronzo RA, Ferrannini E, Hendler R, Felig P, Wahren J, Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia. Diabetes 32: 35-45, 1983.

176. Cherrington AD, Stevenson RW, Steiner KE, Davis MA, Myers SR, Adkins BA, Abumrad NN, Williams PE. Insulin, glucagon, and glucose as regulators of hepatic glucose uptake and production in vivo. Diabetes Metab Rev 3:307-332, 1987.

177. Bergman RN, Bucolo RJ. Interaction of insulin and glucose in the control of hepatic glucose balance. Am J Physiol 227:1314-1322, 1974.

178. Mevorach M, Giacca A, Aharon Y, Hawkins M, Shamoon H, Rossetti L. Regulation of endogenous glucose production by glucose per se is impaired in type 2 diabetes mellitus. J Clin Invest 102:744-753, 1998.

179. Basu R, Basu A, Nielsen M, Shah P, Rizza RA. Effect of overnight restoration of euglycemia on glucose effectiveness in type 2 diabetes mellitus. J Cin Endocrinol Metab 84:2314-2319, 1999.

180. Waldhausl W, Bratusch-Marrain P, Gasic S, Korn A, Nowotny P. Insulin production rate, hepatic insulin retention, and splanchnic carbohydrate metabolism after oral glucose ingestion in hyperinsulinemic type II (non-insulin dependent) diabetes mellitus. Diabetologia 23: 6-15, 1982.

181. Consoli A, Nurjahn N, Capani F, Gerich J. Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes 38: 550-556, 1989.

182. Nurjhan N, Consoli A, Gerich J. Increased lipolysis and its consequences on gluconeogenesis in noninsulin-dependent diabetes mellitus. J Clin Invest 89:169-175, 1992.

183. Magnusson I, Rothman D, Katz L, Shulman R, Shulman G. Increased rate of gluconeogenesis in type II diabetes: a 13C nuclear magnetic resonance study. J Clin Invest 90:1323-1327, 1992.

184. Gastaldelli A, Baldi S, Pettiti M, Toschi E, Camastra S, Natali A, Landau BR, Ferrannini E. Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes 49:1367-1373, 2000.

185. Gastaldelli A, Toschi E, Pettiti M, Frascerra S, Qinones-Galvan A, Sironi AM, Natali A, Ferrannini E. Effect of physiological hyperinsulinemia on gluconeogenesis in nondiabetic subjects and in type 2 diabetic patients. Diabetes 50:1807-1812, 2001.

186. Stumvoll M, Perriello G, Nurjhan N, Bucci A, Welle S, Jansson P-A, Dailey G, Bier D, Jenssen T, Gerich J. Glutamine and alanine metabolism in NIDDM. Diabetes 45:863-868, 1996.

187. Baron AD, Schaeffer L, Shragg P, Kolterman OG. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 36:274-283, 1987.

188. Felig P, Wahren J, Hendler R. Influence of maturity-onset diabetes on splanchnic balance after oral glucose ingestion. Diabetes 27: 121-126, 1978.

189. Foley JE. Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus. Diabetes Care 15:773-784, 1992.

190. Matsuda M, DeFronzo RA, Glass L, Consoli A, Giordano M, Bressler P, DelPrato S. Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. Metabolism 51:1111-1119, 2002.

191. Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in NIDDM. J Clin Endocrinol Metab 81:4059-4067, 1996.

192. Clore JN, Stillman J, Sugerman H. Glucose-6-phosphatase flux in vitro is increased in type 2 diabetes. Diabetes 49:969-974, 2000.

193. O'Brien RM, Granner DK. PEPCK gene as model of inhibitory effects of insulin on gene transcription. Diabetes Care 13:327-339, 1990.

194. Sutherland C, O'Brien RM, Granner DK. New connections in the regulation of PEPCK gene expression by insulin. Phil Trans R Soc Long B 351:191-199, 1996.

195. Cersosimo E, Garlick P, Ferretti J. Regulation of splanchnic and renal substrate supply by insulin in humans. Metabolism 49:676-683, 2000.

196. Moller N. Rizza RA. Ford GC. Nair KS. Assessment of postabsorptive renal glucose metabolism in humans with multiple glucose tracers. Diabetes. 50:747-751, 2001

197. Meyer C, Stumvoll M, Nadkarni V, Dostou J, Mitrakou A, Gerich J. Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. J Clin Invest 102:619-624, 1998.

198. Bjorntorp P, Berchtold P, Holm J. The glucose uptake of human adipose tissue in obesity. Eur J Clin Invest 1:480-485, 1971.

199. Frayn KN, Coppack SW, Humphreys SM, Whyte PL. Metabolic characteristics of human adipose tissue in vivo. Clin Sci 76:509-516, 1989.

200. Campbell P, Mandarino L, Gerich J. Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose intake in non-insulin-dependent diabetes mellitus. Metabolism 37:1 5-22, 1988.

201. Capaldo B, Napoli R, Dimarino L, Picardi A, Riccardi G, Sacca L. Quantitation of forearm glucose and free fatty acid (FFA) disposal in normal subjects and type 2 diabetic patients: evidence against an essential role for FFA in the pathogenesis of insulin resistance. J Clin Endocrinol Metab 67:893-898, 1988.

202. Jackson RA, Perry G, Rogers J, Advoni U, Pilkington TRE. Relationship between the basal glucose concentration, glucose tolerance, and forearm glucose uptake in maturity onset diabetes. Diabetes 22:751-761, 1973.

203. Utriainen T. Takala T. Luotolahti M. Ronnemaa T. Laine H. Ruotsalainen U. Haaparanta M. Nuutila P. Yki-Jarvinen H. Insulin resistance characterizes glucose uptake in skeletal muscle but not in the heart in NIDDM. Diabetologia. 41:555-559, 1998.

204. Firth RG, Bell PM, Marsh HM, Hansen I, Rizza RA. Postprandial hyperglycemia in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 77:1525-1532, 1986.

205. Ferrannini E, Simonson DC, Katz LD, Reichard G Jr, Bevilacqua S, Barrett EJ, Olsson M, DeFronzo RA. The disposal of an oral glucose load in patients with non-insulin dependent diabetes. Metabolism 37:79-85, 1988.

206. Huang SC, Phelps ME, Hoffman EJ, Sideris K, Selin CJ, Kuhl DE. Non-invasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol 238:E69-E82, 1980.

207. Kelley D, Mitrakou A, Marsh H, Schwenk F, Benn J, Sonnenberg G, Arcangeli M, Aoki T, Sorensen J, Berger M, Sonksen P, Gerich J. Skeletal muscle glycolysis oxidation, and storage of an oral glucose load. J Clin Invest 81:1563-1571,1988.

208. Jackson RA, Roshania RD, Hawa MI, Sim BM, DiSilvio L. Impact of glucose ingestion on hepatic and peripheral glucose metabolism in man: an analysis based on simultaneous use of the forearm and double isotope techniques. J Clin Endocrinol Metab 63:541-549, 1986.

209. Jackson RA, Perry G, Rogers J, Advoni U, Pilkington TRE. Relationship between the basal glucose concentration, glucose tolerance, and forearm glucose uptake in maturity onset diabetes. Diabetes 22:751-761, 1973.

210. Shimazu T. Neuronal regulation of hepatic glucose metabolism in mammals. Diabetes Metab Rev 3:185-206, 1987.

211. McMahon V, Marsh HM, Rizza RA. Effects of basal insulin supplementation on disposition of mixed meal in obese patients with NIDDM. Diabetes 38:291-303, 1989.

212. Basu A, Basu R, Shah P, Vella A, Johnson M, Nair KS, Jensen MD, Schwenk WF, Rizza RA. Effects of type 2 diabetes on the ability of insulin and glucose to regulate splanchnic and muscle glucose metabolism. Evidence for a defect in hepatic glucokinase activity. Diabetes 49:272-283, 2000.

213. Ludvik B, Nolan JJ, Roberts A, Baloga J, Joyce M, Bell Jo M, Olefsky JM. Evidence for decreased splanchnic glucose uptake after oral glucose administration in non-insulin-dependent diabetes mellitus. J Clin Invest 100:2354-2361, 1997.

214. Reaven GM, Brand RJ, Ida Chen Y-D, Mathur AK, Goldfine I. Insulin resistance and insulin secretion are determinants of oral glucose tolerance in normal individuals. Diabetes 42:1324-1332, 1993.

215. Shulman GI, Rothman DL, Jue T, Stein P, DeFronzo RA, Shulman RG. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. New Engl J Med 322:223-228, 1990.

216. Bonadonna RC, Bonora E. Glucose and free fatty acid metabolism in human obesity: relationships to insulin resistance. Diabetes Rev 5:21-51, 1997.

217. Reaven GM, Chen Y-DI, Donner CC, Fraze E, Hollenbeck CB. How insulin resistant are patients with non-insulin-dependent diabetes mellitus? J Clin Endocrinol Metab 61:32-36, 1985.

218. Lillioja A, Mott DM, Zawadzki JK, Young AA, Abbott WG, Bogardus C. Glucose storage is a major determinant of in vivo 'insulin resistance' in subjects with normal glucose tolerance. J Clin Endocrinol Metab 62: 922-927, 1986.

219. Tripathy D, Carlsson M, Almgren P, Osomaa B, Raskinen M-R, Tuomi T, Groop LC. Insulin secretion and insulin sensitivity in relation to glucose tolerance. Lessons from the Botnia Study. Diabetes 49:975-980, 2000.

220. Zimmet PZ. The pathogenesis and prevention of diabetes in adults. Diabetes Care 18:1050-1064, 1995.

221. Mokdad AH, Ford ES, Bowman BA, Nelson DE, Engelgau MM, Vinicor F, Marks JS: Diabetes trends in the United States, 1990-1998. Diabetes Care 23:1278-1283, 2000.

222. Reaven GM, Hollenbeck C, Jeng C-Y, Wu MS, Chen Y-DI: Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 hours in patients with NIDDM. Diabetes 37:1020-1024, 1988.

223. Thiebaud D, DeFronzo RA, Jacot E, Golay A, Acheson K, Maeder E, Jequier E, Felber JP. Effect of long-chain triglyceride infusion on glucose metabolism in man. Metabolism 31:1128-1136, 1982.

224. Kelley De, Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance. A reexamination. Diabetes 49:677-683, 2000.

225. Kashyap S, Belfort R, Pratipanawatr T, Berria R, Pratipanawatr W, Bajaj M, Mandarino L, DeFronzo R, Cusi K: Chronic elevation in plasma free fatty acids impairs insulin secretion in non-diabetic offspring with a strong family history of T2DM. Diabetes 51(Suppl 2):A12, 2002.

226. Carpentier A. Mittelman SD. Bergman RN. Giacca A. Lewis GF. Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes. Diabetes. 49:399-408, 2000.

227. Reaven GM. The fourth Musketeer - from Alexandre Dumas to Calude Bernard. Diabetologia 38:3-13, 1995.

228. Goodpaster BH, Thaete FL, Kelley BE. Thigh adipose tissue distribution is associated with insulin resistance in obesity and in type 2 diabetes mellitus. Am J Clin Nutr 71:885-892, 2000.

229. Greco AV, Mingrone G, Giancaterini A, Manco M, Morroni M, Cinti S, Granzotto M, Vettor R, Camastra S, Ferrannini E. Insulin resistance in morbid obesity. Reversal with intramyocellular fat depletion. Diabetes 51:144-151, 2002.

230. Ryysy L, Hakkinen AM, Goto T, Vehkavaara S, Westerbacka J, Halavaara J, Yki-Jarvinen H: Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49:749-758, 2000.

231. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87:2784-2791, 2002.

232. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1785-789, 1963.

233. Wititsuwannakul D, Kim K. Mechanism of palmityl coenzyme A inhibition or liver glycogen synthase. J Biol Chem 252:7812-7817, 1977.

234. Golay A, Felber JP, Meyer HU, Curchod B, Maeder E, Jequier E. Study on lipid metabolism in obesity diabetes. Metabolism 33:111-116, 1984.

235. Felber JP, Meyer HU, Curchod B, Iselin HU, Rousselle J, Maeder E, Pahud P, Jequier E.. Glucose storage and oxidation in different degrees of human obesity measured by continuous indirect calorimetry. Diabetologia 20: 39-44, 1981.

236. Roden M, Krssak M, Stingl H, Gruber S, Hofer A, Furnsinn C, Moser E, Waldhausl W. Rapid impairment of skeletal muscle glucose transport/phosphorylation by free fatty acids in humans. Diabetes 48:358-364, 1999.

237. Bonadonna RC, Groop LC, Zych K, Shank M, and DeFronzo RA. Dose dependent effect of insulin on plasma free fatty acid turnover and oxidation in humans. Am J Physiol 22:736-750, 1990.

238. Boden G. Free fatty acids, insulin resistance, and type 2 diabetes mellitus. Proc Assoc Am Physicians 111:241-248, 1999.

239. Boden G, Chen X, Ruiz J, White JV, Rossetti L. Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest 93:2438-2446, 1994.

240. Krssak M, Falk Petersen K, Dresner A, DiPietro L, Vogel SM, Rothman DL, Roden M, Shulman GI. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1HNMR spectroscopy study. Diabetologia 42:113-116, 1999.

241. Jacobs S, Machann J, Rett K, Brechtel K, Volk A, Renn W, Maerker E, Matthaei S, Schick F, Claussen CD, Hearing H-U. Association of increased intramyocellular lipid content with insulin resistance in lean non-diabetic offspring of type 2 diabetic subjects. Diabetes 48:1113-1119, 1999.

242. Kelley De, Goodpaster BH. Skeletal muscle triglyceride. An aspect of regional adiposity and insulin resistance. Diabetes Care 24:933-941, 2001.

243. Kelley DE, Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance. Diabetes 49:677-683, 2000.

244. Itani SI, Ruderman NB, Schmieder F, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkB-a. Diabetes 51:2005-2011, 2002.

245. Ellis BA, Poynten A, Lowy AJ, Furler SM, Chisholm DJ, Kraegen EW, Cooney GJ. Long-chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle. Am J Physiol 279:E554-E560, 2000.

246. De Fea K, Roth RA. Protein kinase C modulation of insulin receptor substrate-1 tyrosine phosphorylation requires serine 612. Biochemistry 36:12939-12947, 1997.

247. Ravichandran LV, Esposito DL, Chen J, Quon MJ. PKC-zeta phosphorylates IRS-1 and impairs its ability to activate P-3-kinase in response to insulin. J Biol Chem 276:3543-3549, 2001.

248. Kruszynska YT, Worrall DS, Ofrecio J, Frias JP, Macaraeg G, Olefsky JM. Fatty acid-induced insulin resistance: decreased muscle PI3K activation but unchanged Akt phosphorylation. J Clin Endocrinol Metab 87:226-234, 2002.

249. Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline SW, Slezak LA, Andersen DK, Hundal RS, Rothman DL, Petersen KF, Shulman GI. Effects of free fatty acids on glucose transport and IRS-1 associated phosphatidylinositol 3-kinase activity. J Clin Invest 103:253-259, 1999.

250. Thompson AL, Cooney GJ. Acyl-CoA inhibition of hexokinase in rat and human skeletal muscle is a potential mechanism of lipid-induced insulin resistance. Diabetes 49:1761-1764, 2000.

251. Tippett PS, Neet KE. An allosteric model for the inhibition of glucokinase by long chain acyl coenzyme A. J Biol Chem 257:14846-14852, 1982.

252. Schmitz-Peiffer C, Craig DL, Biden TJ. Ceramide generation is sufficient to account for the inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate. J Biol Chem 274:24202-24210, 1999.

253. Baron AD. Hemodynamic actions of insulin. Am J Physiol 267:E187-E202, 1994.

254. Mather K, Laakso M, Edelman S, Hook G, Baron A. Evidence for physiological coupling of insulin-mediated glucose metabolism and limb blood flow. Am J Physiol Endocrinol Metab 279:E1264-E1270, 2000.

255. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 94:1172-1179, 1994.

256. Utriainen T, Nuutila P, Takala T, Vicini P, Ruotsalainen U, Ronnemaa T, Tolvanen T, Raitakari M, Haaparanta M, Kirvela O, Cobelli C, Yki-Jarvinen H. Intact stimulation of skeletal muscle blood flow, its heterogeneity and redistribution, but not of glucose uptake in non-insulin-dependent diabetes mellitus. J Clin Invest 100:777-785, 1997.

257. Steinberg HO, Paradisi G, Hook G, Crowder K, Cronin J, Baron AD. Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes 49:1231-1238, 2000.

258. Kreutzenberg SV, Crepaldi C, Marchetto S, Calo L, Tiengo A, Del Prato S, Avogaro A. Plasma free fatty acids and endothelium-dependent vasodilation: effect of chain-length and cyclooxygenase inhibition. J Clin Endocrinol Metab 85:793-798, 2000.

259. Davda RK, Chandler LJ, Guzman NJ. Protein kinase C modulates receptor-independent activation of endothelial nitric oxide synthase. Eur J Pharmacol 266:237-244, 1994.

260. Zeng G, Quon MJ. Insulin stimulated production of nitric oxide is inhibited by wortmannin: direct measurement in vascular endothelial cells. J Clin Invest 98:894-898, 1996.

261. Exton JH, Corbin JG, Park CR. Control of gluconeogenesis in liver. IV. Differential effects of fatty acids and glucagon on ketogenesis and gluconeogenesis in the perfused rat liver. J Biol Chem 244:4095-4102, 1969.

262. Bahl JJ, Matsuda M, DeFronzo RA, Bressler R. In vitro and in vivo suppression of gluconeogenesis by inhibition of pyruvate carboxylase. Biochem Pharmacol 53:67-74, 1997.

263. Massillon D, Barzailai N, Hawkins M, Prus-Wetheimer D, Rossetti L. Induction of hepatic glucose-6-phosphatase gene expression by lipid infusion. Diabetes 46:153-157, 1997.

264. Chen X, Iqbal N, Boden G. The effect of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects. J Clin Invest 103:365-372, 1999.

265. Roden M, Stingl H, Chandramouli V, Schumann WC, Hofer A, Landau BR, Nowotny P, Waldhausl W, Shulman GI. Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans. Diabetes 49:701-707, 2000.

266. Lewis GF. Vranic M. Harley P. Giacca A. Fatty acids mediate the acute extrahepatic effects of insulin on hepatic glucose production in humans. Diabetes. 46:1111-11119, 1997.

267. Rebrin K. Steil GM. Getty L. Bergman RN. Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin. Diabetes. 44:1038-45, 1995.

268. Ferrannini E, Barrett EJ, Bevilacqua S, and DeFronzo RA. Effect of fatty acids on glucose production and utilization in man. J Clin Invest 72:1737-1747, 1983.

269. Bevilacqua S, Bonadonna R, Buzzigoli G, Boni C, Ciociaro D, Maccari F, Giorico MA, Ferrannini E: Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects. Metabolism 36:502-506, 1987.

270. Golay A, Swislocki ALM, Chen Y-DI, Reaven GM: Relationships between plasma free fatty acid concentration, endogenous glucose production, and fasting hyperglycemia in normal and non-insulin-dependent diabetic individuals. Metabolism 36:692-696, 1987.

271. Baron AD, Schaeffer L, Shragg P, Kolterman OG: Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 36:274-283, 1987.

272. Bjorntorp P. Metabolic implications of body fat distribution. Diabetes Care 14:1132-1143, 1991.

273. Arner P. Regional adipocity in man. J Endocrinol 155:191-192, 1997.

274. Saltiel AR, Kahn CR. Insulin signaling and the regulation of glucose and lipid metabolism. Nature 414:799-806, 2001.

275. Virkamaki A, Ueki K, Kahn CR. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 103:931-943, 1999.

276. Pessin JE, Saltiel AR. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 106:165-169, 2000.

277. Whitehead JP, Clark SF, Urso B, James DE. Signalling through the insulin receptor. Current Opinion in Cell Biology 12:222-228, 2000.

278. Wilden PA, Kahn CR. The level of insulin receptor tyrosine kinase activity modulates the activities of phosphatidylinositol 3-kinase, microtubule-associated protein, and S6 kinases. Mol Endo 8:558-567, 1994.

279. Haring HU, Mehnert H. Pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: candidates for a signal transmitter defect causing insulin resistance of the skeletal muscle. Diabetologia 36:176-182, 1993.

280. Wajtaszewski JFP, Hansen BF, Kiens B, Richter EA. Insulin signaling in human skeletal muscle. Time course and effect of exercise. Diabetes 46:1775-1781, 1997.

281. Shepherd PR, Kahn BB. Glucose transporters and insulin action. Implications for insulin resistance and diabetes mellitus. N Engl J Med 341:248-257, 1999.

282. Garvey WT. Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction, and the glucose transport effector system. Am J Med 105:331-345, 1998.

283. Chou DK, Dull TJ, Russell DS, Gherzi R, Lebwohl D, Ullrich A, Rosen OM. Human insulin receptors mutated at the ATP-binding site lack protein tyrosine kinase activity and fail to mediate postreceptor effects of insulin. J Biol Chem 262:1842-1847, 1987.

284. Ebina Y, Araki E, Tiara F, Shimada F, Mari M, Craik CS, Siddle K, Pierce SB, Roth RA, Rutter WJ. Replacement of lysine residue 1030 in the putative ATP-binding region of the insulin receptor abolishes insulin and antibody-stimulated glucose uptake and receptor kinase activity. Proc Natl Acad Sci USA 84:704-708, 1987.

285. Ellis LE, Clauser E, Morgan ME, Roth RA, Rutter WJ. Replacement of insulin receptor tyrosine residues 1162 and 1163 compromises insulin-stimulated kinase activity and uptake of 2-dexoyglucose. Cell 45:721-732, 1986.

286. White MF, Livingston JN, Backer JM, Lauria V, Duli TJ, Ullrich A, Kahn DR. Mutation of the insulin receptor at tyrosine 960 inhibits signal transmission but does not affect its tyrosine kinase activity. Cell 54:641-649, 1992.

287. Kerouz, N.J., Horsch, D., Pons, S., Kahn, C.R. Differential regulation of insulin receptor substrates-1 and -2 (IRS-1 and IRS-2) and phosphatidylinositol 3-kinase isoforms in liver and muscle of the obese diabetic (ob/ob) mouse. J Clin Invest 100:3164-3172, 1997

288. Baumann CA. Ribon V. Kanzaki M. Thurmond DC. Mora S. Shigematsu S. Bickel PE. Pessin JE. Saltiel AR. CAP defines a second signalling pathway required for insulin-stimulated glucose transport. Nature. 407:202-207, 2000.

289. Chiang SH. Baumann CA. Kanzaki M. Thurmond DC. Watson RT. Neudauer CL. Macara IG. Pessin JE. Saltiel AR. Insulin-stimulated GLUT4 translocation requires the CAP-dependent activation of TC10. Nature. 410:944-948, 2001.

290. Backer JM, Myers Jr MG, Shoelson SE, Chin DJ, Sun XJ, Miralpeix M., Hu P, Margolis B., Skoinik EY, Schlessinger J, White, MF. The phosphatidylinositol 3' kinase is activated by association with IRS-1 during insulin stimulation. EMBO J 11:3469-3479, 1992.

291. Sun XJ, Miralpeix M, Myers Jr MG, Glasheen EM, Backer JM, Kahn CR, White MF. The expression and function of IRS-1 in insulin signal transmission. J Biol Chem 267-22662-22672, 1992.

292. Cross DA. Alessi DR. Cohen P. Andjelkovich M. Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 378:785-789, 1995.

293. Brady MJ. Nairn AC. Saltiel AR. The regulation of glycogen synthase by protein phosphatase 1 in 3T3-L1 adipocytes. Evidence for a potential role for DARPP-32 in insulin action. J Biol Chem. 272:29698-703, 1997.

294. Okada T, Sakuma L, Fukui Y, Hazeki O, Ui M. Essential role of phosphatidylinositol 3-kinase in insulin-induced glucose transport and antilipolysis in rat adipocytes. J Biol Chem 269:3568-3573, 1994.

295. Cross D, Alessi D, Vandenheed J, McDowell H, Hundal H, and Cohen P. The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmannin but not rapamycin. Biochem J 303:21-26, 1994.

296. Osawa H, Sutherland C, Robey R, Printz R, Granner D. Analysis of the signaling pathway involved in the regulation of hexokinase II gene transcription by insulin. J Biol Chem 271:16690-16694, 1996.

297. Thomas G. Hall MN. TOR signalling and control of cell growth. Current Opinion in Cell Biology. 9:782-7, 1997.

298. Nave BT. Ouwens M. Withers DJ. Alessi DR. Shepherd PR. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J. 344(Pt 2):427-31, 1999

299. Miron M. Verdu J. Lachance PE. Birnbaum MJ. Lasko PF. Sonenberg N. The translational inhibitor 4E-BP is an effector of PI(3)K/Akt signalling and cell growth in Drosophila. Nature Cell Biology. 3:596-601, 2001

300. Shimomura I. Bashmakov Y. Ikemoto S. Horton JD. Brown MS. Goldstein JL. Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc Nat Acad Sci USA. 96:13656-61, 1999

301. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T, DeFronzo RA, Kahn CR, Mandarino LJ. Insulin resistance differentially affects the PI 3-kinase and MAP kinase-mediated signaling in human muscle. J Clin Invest 105:311-320, 2000.

302. Hsueh WA, Law RE. Insulin signaling in the arterial wall. Am J Cardiol 84:21J-24J, 1999.

303. Xi X-P, Graf K, Goetze S, HsuehWA, Law RE. Inhibition of MAP kinase blocks insulin-mediated DNA synthesis and transcriptional activation of c-fos by Elk-1 in vascular smooth muscle cells. FEBS Lett 417:283-286, 1997.

304. Boulton TG. Nye SH. Robbins DJ. Ip NY. Radziejewska E. Morgenbesser SD. DePinho RA. Panayotatos N. Cobb MH. Yancopoulos GD. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell. 65:663-75, 1991.

305. Lazar DF. Wiese RJ. Brady MJ. Mastick CC. Waters SB. Yamauchi K. Pessin JE. Cuatrecasas P. Saltiel AR. Mitogen-activated protein kinase kinase inhibition does not block the stimulation of glucose utilization by insulin. J Biol Chem. 270:20801-7, 1995.

306. Dorrestijn J, Ouwens DM, Van den Berghe N, Box JL, Maassen JA. Expression of dominant-negative Ras mutant does not affect stimulation of glucose uptake and glycogen synthesis by insulin. Diabetologia 39:558-563, 1996.

307. Dent P, Lavoinne A, Nakielny S, Caudwell FB, Watt P, Cohen F. The molecular mechanisms by which insulin stimulates glycogen synthesis in mammalian skeletal muscle. Nature 348:302-307, 1990.

308. Cohen P. The structure and regulation of protein phosphatases. Annu Rev Biochem 58:453-508, 1989.

309. Newgard CB, Brady MJ, O'Doherty RB, Saltiel AR. Organizing glucose disposal. Emerging roles of the glycogen targeting subunits of protein phosphatase-1. Diabetes 49:1967-1977, 2000.

310. Sheperd PR, Nave BT, Siddle K. Insulin stimulation of glycogen synthesis and glycogen synthase activity is blocked by wortmannin and rapamycin in 3T3L1 adipocytes: evidence for the involvement of phosphoinositide 3 kinase and p70 ribosomal protein S6 kinase. Biochem J 305:25-28, 1995.

311. Freidenberg GR, Henry RR, Klein HH, Reichart DR, Olefsky JM. Decreased kinase activity of insulin receptors from adipocytes of non-insulin-dependent diabetic studies. J Clin Invest 79:240-250, 1987.

312. Caro JF, Sinha MK, Raju SM, Ittoop O, Pories WJ, Flickinger EG, Meelheim D, Dohm GL. Insulin receptor kinase in human skeletal muscle from obese subjects with and without non-insulin dependent diabetes. J Clin Invest 1987;79:1330-7.

313. Caro JF, Ittoop O, Pories WJ, Meelheim D, Flickinger EG, Thomas F, Jenquin M, Silverman JF, Khazanie PG, Sinha MK. Studies on the mechanism of insulin resistance in the liver from humans with non-insulin-dependent diabetes. Insulin action and binding in isolated hepatocytes, insulin receptor structure, and kinase activity. J Clin Invest 78: 249-58, 1986.

314. Molina JM, Ciaraldi TP, Brady D, Olefsky JM. Decreased activation rate of insulin-mediated glucose transport in adipocytes from obese and NIDDM subjects. Diabetes 38:991-995, 1989.

315. Trichitta V, Brunetti A, Chiavetta A, Benzi L, Papa V, Vigneri R. Defects in insulin-receptor internalization and processing in monocytes of obese subjects and obese NIDDM patients. Diabetes 38:1579-1584, 1989.

316. Comi RJ, Grunberger G, Gorden P. Relationship of insulin binding and insulin-stimulated tyrosine kinase activity is altered in type II diabetes. J Clin Invest 79: 453-462, 1987.

317. Klein HH, Vestergaard H, Kotzke G, Pedersen O. Elevation of serum insulin concentration during euglycemic hyperinsulinemic clamp studies leads to similar activation of insulin receptor kinase in skeletal muscle of subjects with and without NIDDM. Diabetes 344:1310-1317, 1995.

318. Obermaier-Kusser B, White MF, Pongratz DE, Su Z, Ermel B, Muhlbacher C, Haring HU. A defective intramolecular autoactivation cascade may cause the reduced kinase activity of the skeletal muscle insulin receptor from patients with non-insulin-dependent diabetes mellitus. J Biol Chem 264:9497-9503, 1989.

319. Arner P, Einarsson K, Ewerth S, Livingston J, Studies on the human liver insulin receptor in non-insulin-dependent diabetes mellitus. J Clin Invest 77: 1716-1718, 1986.

320. Kashiwagi A, Verso MA, Andrews J, Vasquez B, Reaven G, Foley JE. In vitro insulin resistance of human adipocytes isolated from subjects with non-insulin-dependent diabetes mellitus. J Clin Invest 72: 1246-1254, 1983.

321. Lonnroth P, Digirolamo M, Krotkiewski M, Smith U. Insulin binding and responsiveness in fat cells from patients with reduced glucose tolerance and type II diabetes. Diabetes 32:748-754, 1983.

322. Olefsky JM, Reaven GM. Insulin binding in diabetes. Relationships with plasma insulin levels and insulin sensitivity. Diabetes 26:680-688, 1977.

323. Cocozza S, Procellini A, Riccardi G, Monticelli A, Condorelli G, Ferrara A, Pianese L, Miele C, Capaldo B, Beguinot F, Varrone S. NIDDM associated with mutation in tyrosine kinase domain of insulin receptor gene. Diabetes 41:521-526, 1992.

324. Moller DE, Yakota A, Flier JS. Normal insulin receptor cDNA sequence in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetes 38:1496-1500, 1989.

325. Kusari J, Verma US, Buse JB, Henry RR, Olefsky JM. Analysis of the gene sequences of the insulin receptor and the insulin-sensitive glucose transporter (GLUT4) in patients with common-type non-insulin-dependent diabetes mellitus. J Clin Invest 88:1323-1330, 1991.

326. Nyomba BL, Ossowski VM, Bogardus C, Mott DM. Insulin-sensitive tyrosine kinase relationship with in vivo insulin action in humans. Am J Physiol 258: E964-E974, 1990.

327. Nolan JJ, Friedenberg G, Henry R, Reichart D, Olefsky JM. Role of human skeletal muscle insulin receptor kinase in the in vivo insulin resistance of noninsulin-dependent diabetes and obesity. J Clin Endocrinol Metab 78:471-477, 1994.

328. Krook A, Bjornholm M, Galuska D, Jiang XJ, Fahlman R, Myers MG, Wallberg-Henriksson H, Zierath JR. Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients. Diabetes 49:284-292, 2000.

329. Bak JF, Moller N, Schmitz O, Saaek A, Pedersen O. In vivo insulin action and muscle glycogen synthase activity in type 2 (non insulin dependent) diabetes mellitus: effects of diet treatment. Diabetologia 35:777-794, 1992.

330. Freidenberg GR, Reichart D, Olefsky JM, Henry RR. Reversibility of defective adipocyte insulin receptor kinase activity in non-insulin dependent diabetes mellitus. Effect of weight loss. J Clin Invest 82:1398-1406, 1988.

331. Kellerer M, Kroder G, Tippmer S, Berti L, Kiehn L, Mosthaf L, Haring H. Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts. Diabetes 43:447-453, 1994.

332. Pratipanawatr W, Pratipanawatr T, Cusi K, Berria R, Adams JM, Jenkinson CP, Maezono K, DeFronzo RA, Mandarino LJ. Skeletal muscle insulin resistance in normoglycemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin-stimulated insulin receptor substrate-1 tyrosine phosphorylation. Diabetes 50:2572-2578, 2001.

333. Laville M, Auboeuf D, Khalfallah Y, Vega N, Riou JP, Vidal H. Acute regulation by insulin of phosphatidylinositol-3-kinase, Rad, Glut 4, and lipoprotein lipase in mRNA levels in human muscle. J Clin Invest 98:43-49,1996.

334. Kim Y-B, Nikoulina S, Ciaraldi TP, Henry RR, Kahn BB. Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes. J Clin Invest 104:733-741, 1999.

335. Andreelli F, Laville M, Ducluzeau P-H, Vega N, Vallier P, Khalfallah Y, Riou J-P, Vidal H. Defective regulation of phosphatidylinositol-3-kinase gene expression in skeletal muscle and adipose tissue of non-insulin-dependent diabetes mellitus patients. Diabetologia 42:358-364, 1999.

336. Folli F, Saad JA, Backer JM, Kahn CR. Regulation of phosphatidylinositol 3-kinase activity in liver and muscle of animal models of insulin-resistant and insulin-deficient diabetes mellitus. J Clin Invest 92:1787-1794, 1993.

337. Imai Y, Philippe N, Accili D, Taylor SI. Expression of variant forms of insulin receptor substrate-1 identified in patients with noninsulin dependent diabetes mellitus. J Clin Endocrinol Metab 82:4201-4207, 1997.

338. Hitman GA, Hawrammi K, McCarthy MI, Viswanathan M, Snehalatha C, Ramachandran A, Tuomilehto J, Tumilehto-Wolf E, Nissenen A, Pedersen O. Insulin receptor substrate-1 gene mutations in NIDDM: implication for the study of polygenic disease. Diabetologia 38:481-486, 1995.

339. Pratley RE. Thompson DB. Prochazka M. Baier L. Mott D. Ravussin E. Sakul H. Ehm MG. Burns DK. Foroud T. Garvey WT. Hanson RL. Knowler WC. Bennett PH. Bogardus C. An autosomal genomic scan for loci linked to prediabetic phenotypes in Pima Indians. J Clin Invest. 101:1757-64, 1998.

340. Jiang ZY. Lin YW. Clemont A. Feener EP. Hein KD. Igarashi M. Yamauchi T. White MF. King GL. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest. 104:447-57, 1999.

341. Sasaoka T. Draznin B. Leitner JW. Langlois WJ. Olefsky JM. Shc is the predominant signaling molecule coupling insulin receptors to activation of guanine nucleotide releasing factor and p21ras-GTP formation. J Biol Chem 269:10734-8, 1994.

342. De Fea K. Roth RA. Modulation of insulin receptor substrate-1 tyrosine phosphorylation and function by mitogen-activated protein kinase. J Biol Chem 272:31400-6, 1997.

343. Dunaif A. Xia J. Book CB. Schenker E. Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 96:801-10, 1995.

344. Kono T, Robinson FW, Blevins TL, Ezaki O. Evidence that translocation of the glucose transport activity is the major mechanism of insulin action on glucose transport fat cells. J Biol Chem 257: 10942-10947, 1982.

345. Bell Gl, Kayano T, Buse JB, Burant CF, Takeda J, Lin D, Fikomoto H, Seino S. Molecular biology of mammalian glucose transporters. Diabetes Care 13:198-200, 1990.

346. Joost H-G, Bell GI, Best JD, Birnbaum MJ, Charron MJ, Chen YT, Doege H, James DE, Lodish HF, Moley KH, Moley JF, Mueckler M, Rogers S, Schurmann A, Seino S, Thorens B. Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators. Am J Physiol Endocrinol Metab 282:E974-E976, 2002.

347. Colowick SP. The hexokinases. In Boyer PD (ed.) The Enzymes, vol. 9. New York: Academic Press, pp 1-48, 1973.

348. Printz RL, Koch S, Potter LR, O'Doherty RM, Tiesinga JJ, Moritz S, Granner DK. Hexokinase II mRNA and gene structure, regulation by insulin, and evolution. J Biol Chem 268:5209-5219, 1993.

349. Rogers PA, Fisher RA, Harris H. An electrophoretic study of the distribution and properties of human hexokinases. Biochem Genet 13:857-866, 1975.

350. Magnuson MA, Andreone IL, Printz RL, Koch S, Granner DK. The glucokinase gene: structure and regulation by insulin. Proc Natl Acad Sci USA 86: 4838-4842, 1989.

351. Matchinsky FM. Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes 45:223-241, 1996.

352. Mandarino LJ, Campbell PJ, Gottesman IS, Gerich JE. Abnormal coupling of insulin receptor binding in non-insulin-dependent diabetes. Am J Physiol 247: E688-E692, 1984.

353. Garvey WT, Huecksteadt TP, Mattaei S, Olefsky JM. Role of glucose transporters in the cellular insulin resistance of type II non-insulin dependent diabetes mellitus. J Clin Invest 81:1528-1536, 1988.

354. Zierath JR, He L, Guma A, Odegoard Wahlstrom E, Klip A, Wallenberg-Henriksson H. Insulin action on glucose transport and plasma membrane GLUT4 content in skeletal muscle from patients with NIDDM. Diabetologia 39:1180-1189, 1996.

355. Krook A, Bjornholm M, Galuska D, Jiang XJ, Fahlman R, Myers MG, Wallenberg-Henriksson H, Zierath JR. Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients. Diabetes 49:284-282, 2000.

356. Andreasson K, Galuska D, Thorne T, Sonnenfeld T, Wallberg-Henriksson H. Decreased insulin-stimulated 3-O-methylglucose transport in in vitro incubated muscle strips from type II diabetic subjects. Acta Physiol Scan 142:255-260, 1991.

357. Kahn BB, Shulman GI, DeFronzo RA, Cushman SW, Rossetti L. Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression. J Clin Invest 87:561-570, 1991.

358. Pedersen O, Bak J, Andersen P, Lund S, Moller DE, Flier JS, Kahn BB. Evidence against altered expression of GLUT1 or GLUT4 in skeletal muscle of patients with obesity or NIDDM. Diabetes 39:865-870, 1990.

359. Eriksson J, Koranyi L, Bourey R, Schalin-Jantti C, Widen E, Mueckler M, Permutt AM, Groop LC. Insulin resistance in type 2 (non-insulin-dependent) diabetic patients and their relatives is not associated with a defect in the expression of the insulin-responsive glucose transporter (GLUT-4) gene in human skeletal muscle. Diabetologia 35:143-147, 1992.

360. Schalin-Jantti C, Yki-Jarvinen H, Koranyi L, Bourey R, Lindstrom J, Nikula-Ijas P, Franssila-Kallunki A, Groop LC. Effect of insulin on GLUT-4 mRNA and protein concentrations in skeletal muscle of patients with NIDDM and their first-degree relatives. Diabetologia 37:401-407, 1994.

361. Garvey WT, Maianu L, Hancock JA, Golichowski AM, Baron A. Gene expression of glut4 in skeletal muscle from insulin-resistant patients with obesity, IGT, GDM, and NIDDM. Diabetes 41:465-475, 1992.

362. Kusari J, Verma US, Buse JB, Henry RR, Olefsky JM. Analysis of the gene sequences of the insulin receptor and the insulin-sensitive glucose transporter (GLUT 4) in patients with common type non insulin dependent diabetes mellitus. J Clin Invest 88:1323-1330, 1991.

363. Choi WH, O'Rahilly S, Rees A, Morgan R, Flier JS, Moller DE. Molecular scanning of the insulin-responsive glucose transporter (GLUT 4) gene in patients with non-insulin dependent diabetes mellitus. Diabetes 40:1712-1718, 1991.

364. Sinha M, Raineri-Maldonado C, Buchanan C, Pories W, Carter-Su C, Pilch P, Caro J. Adipose tissue glucose transporters in NIDDM: decreased levels of muscle/fat isoform. Diabetes 40:474-477, 1991.

365. Guma A, Zierath JR, Wallberg-Henriksson H, Klip A. Insulin induces translocation of GLUT-4 glucose transporters in human skeletal muscle. Am J Physiol 268:E613-E622, 1995.

366. Goodyear LJ, Hirschman MF, Napoli R, Calles J, Markuns JF, Ljungqvist O, Horton ES. Glucose ingestion causes GLUT4 translocation in human skeletal muscle. Diabetes 45:1051-1056, 1996.

367. Kelley DE, Mintun MA, Watkins SC, Simoneau J-A, Jadali F, Fredrickson A. The effect of non-insulin-dependent diabetes mellitus and obesity on glucose transport and phosphorylation in skeletal muscle. J Clin Invest 97:2705-2713, 1996.

368. Bonadonna RC, Saccomani MP, Seely L, Zych KS, Ferrannini E, Cobelli C, DeFronzo RA. Glucose transport in human skeletal muscle. The in vivo response to insulin. Diabetes 42:191-198 1993.

369. Bonadonna RC, Del Prato S, Saccomani MP, Bonora E, Gulli G, Ferrannini E, Bier D, Cobelli C, DeFronzo RA. Transmembrane glucose transport in skeletal muscle of patients with non-insulin-dependent diabetes. J Clin Invest 92:486-494, 1993.

370. Bonadonna RC, Del Prato S, Bonora E, Saccomani MP, Gulli G, Natali A, Frascerra S, Pecro N, Ferrannini E, Bier D, Cobelli C, DeFronzo RA. Roles of glucose transport and glucose phosphorylation in muscle insulin resistance of NIDDM. Diabetes 45:915-925, 1996.

371. Napoli R, Hirschman MF, Horton FS. Mechanisms of increased skeletal muscle glucose transport activity after an oral glucose load in rats. Diabetes 44:1362-1368, 1995.

372. Cline GW, Petersen KF, Krssak M, Shen J, Hundal RS, Trajanoski Z, Inzucchi S, Dresner A, Rothman DL, Shulman GI. Impaired glucose transport as a cause of decreased insulin stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 341:240-246, 1999.

373. Williams KV, Price JC, Kelley DE. Interactions of impaired glucose transport and phosphorylation in skeletal muscle insulin resistance. A dose-response assessment using positron emission tomography. Diabetes 50:2069-2079, 2001.

374. Perriott LM, Kono T, Whitesell RR, Knobel SM, Piston DW, Granner DK, Powers AC, May JM. Glucose uptake and metabolism by cultured human skeletal muscle cells: rate-limiting steps. Am J Physiol Endocrinol Metab 281:E72-E80, 2001.

375. Printz RL, Ardehali H, Koch S, Granner DK. Human hexokinase II mRNA and gene structure. Diabetes 44:290-294, 1995.

376. Postic CA, Leturque A, Rencurel F, Printz R, Forest C, Granner D, Girard J. The effects of hyperinsulinemia and hyperglycemia on GLUT4 and hexokinase II mRNA and protein in rat skeletal muscle and adipose tissue. Diabetes 42:922-929, 1993.

377. Jones JP, Dohn GL. Regulation of glucose transporter GLUT-4 and hexokinase II gene transcription by insulin and epinephrine. Am J Physiol (Endocrinol Metab 36):E682-E687, 1997.

378. Mandarino LJ, Printz RL, Cusi KA, Kinchington P, O'Doherty RM, Osawa H, Sewell C, Consoli A, Granner DK, DeFronzo RA. Regulation of hexokinase II and glycogen synthase mRNA, protein, and activity in human muscle. Am J Physiol 269:E701-E708, 1995.

379. Kruszynska YT, Mulford MI, Baloga J, Yu JG, Olefsky JM. Regulation of skeletal muscle hexokinase II by insulin in nondiabetic and NIDDM subjects. Diabetes 47:1107-1113, 1998.

380. Vogt C, Ardehali H, Iozzo P, Yki-Jarvinen H, Koval J, Maezono K, Pendergrass M, Printz R, Granner D, DeFronzo R, Mandarino L. Regulation of hexokinase II expression in human skeletal muscle in vivo. Metabolism 49:814-818, 2000.

381. Vogt C, Yki-Jarvinen H, Iozzo P, Pipek R, Pendergrass M, Koval J, Ardehali H, Printz R, Granner D, DeFronzo RA, Mandarino L. Effects of insulin on subcellular localization of hexokinase II in human skeletal muscle in vivo. J Clin Endocrinol Metab 83:230-234, 1998.

382. Pendergrass M, Fazioni E, Saccomani MP, Collins D, Bonadonna R, Gulli G. In vivo glucose transport and phosphorylation in skeletal muscle is impaired in insulin resistant, normal glucose tolerant offspring of two NIDDM parents. Diabetes 44(suppl 1):197A, 1995.

383. Rothman DL, Shulman RG, Shulman GI. 31P nuclear magnetic resonance measurements of muscle glucose-6-phosphate. Evidence for reduced insulin-dependent muscle glucose transport or phosphorylation activity in non-insulin-dependent diabetes mellitus. J Clin Invest 89:1069-1075, 1992.

384. Halseth AE, Bracy DP, Wasserman DH. Overexpression of hexokinse II increases insulin- and exercise-stimulated muscle glucose uptake in vivo. Am J Physiol 276:E70-E77, 1999.

385. Pendergrass M, Koval J, Vogt C, Yki-Jarvinen H, Iozzo P, Pipek R, Ardehali H, Printz R, Granner D, DeFronzo RA, Mandarino L. Insulin-induced hexokinase II expression is reduced in obesity and NIDDM. Diabetes 47:387-394, 1998.

386. Vestergaard H, Bjorbaek C, Hansen T, Larsen FS, Granner DK, Pedersen O. Impaired activity and gene expression of hexokinase II in muscle from non-insulin-dependent diabetes mellitus patients. J Clin Invest 96:2639-2645, 1995.

387. Ducluzeau P-H, Perretti N, Laville M, Andreelli F, Vega N, Riou J-P, Vidal H. Regulation by insulin of gene expression in human skeletal muscle and adipose tissue. Evidence for specific defects in type 2 diabetes. Diabetes 50:1134-1142, 2001.

388. Lehto M, Huang X, Davis EM, Le Beau MM, Laurila E, Eriksson KF, Bell GI, Groop L. Human hexokinase II gene: exon-intron organization, mutation screening in NIDDM, and its relationship to muscle hexokinase activity. Diabetologia 38:1466-1474, 1995.

389. Laakso M, Malkki M, Kekalainen P, Kuusito J, Deeb SS. Polymorphisms of the human hexokinase II gene: lack of association with NIDDM and insulin resistance. Diabetologia 38:617-622, 1995.

390. Echwald SM, Bjorbaek C, Hansen T, Clausen JO, Vestergaard H, Zierath JR, Printz RL, Granner DK, Pedersen O. Identification of four amino acid substitutions in hexokinase II and studies of relationships to NIDDM, glucose effectiveness, and insulin sensitivity. Diabetes 44:347-353, 1995.

391. Thiebaud D, Jacot E, DeFronzo RA, Maeder E, Jequier E, Felber JP. The effect of graded doses of insulin on total glucose uptake, glucose oxidation, and glucose storage in man. Diabetes 31: 957-963, 1982.

392. Young A, Bogardus C, Wolfe-Lopez D, Mott D. Muscle glycogen synthesis and disposition of infused glucose in humans with reduced rates of insulin-mediated carbohydrate storage. Diabetes 37:303-307, 1988.

393. Avogaro A, Toffolo G, Miola M, Valerio A, Tiengo A, Cobelli C, Del Prato S. Intracellular lactate- and pyruvate-interconversion rates are increased in muscle tissue of non-insulin-dependent diabetic individuals. J Clin Invest 98:108-115, 1996.

394. Del Prato S, Bonadonna RC, Bonora E, Gulli G, Solini A, Shank M, DeFronzo RA. Characterization of cellular defects of insulin action in type 2 (non-insulin-dependent) diabetes mellitus. J Clin Invest 91:484-494, 1993.

395. Bonadonna RC, Groop L, Kraemer N. Ferrannini E, Del Prato S, DeFronzo RA. Obesity and insulin resistance in man. A dose response study. Metabolism 39: 452-459, 1990.

396. Mandarino LJ, Consoli A, Kelley DE, Reilly JP, Nurjhan N. Fasting hyperglycemia normalizes oxidative and nonoxidative pathways of insulin-stimulated glucose metabolism in non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 71:1544-1551, 1990.

397. Kelley DE, Mandarino LJ. Hyperglycemia normalizes insulin-stimulated skeletal muscle glucose oxidation and storage in noninsulin-dependent diabetes mellitus. J Clin Invest 86:1999-2007, 1990.

398. Bogardus C, Lillioja A, Stone K, Mott D. Correlation of muscle glycogen synthase activity and in vivo insulin action in man. J. Clin Invest 1984; 73: 1185-90.

399. Rothman DL, Magnusson I, Cline G, Gerard D, Kahn CR, Shulman RG, Shulman GI. Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 92:983-987, 1995.

400. Vaag A, Henriksen JE, Beck-Nielsen. Decreased insulin activation of glycogen synthase in skeletal muscles in young non-obese Caucasian first-degree relatives of patients with non-insulin-dependent diabetes mellitus. J Clin Invest 89:782-788, 1992.

401. Yki-Jarvinen H, Mott D, Young AA, Stone K, Bogardus C. Regulation of glycogen synthase and phosphorylase activity by glucose and insulin in human skeletal muscle. J Clin Invest 80: 95-100, 1987.

402. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 359(Pt 1):1-16, 2001.

403. Cohen P. The Croonian Lecture 1999. Identification of a protein kinase cascade of major importance in insulin signal transduction. Phil Trans Royal Soc London Series B: Biological Sciences 354:485-495, 1999.

404. Stralfors P, Hiraga A, Cohen P. The protein phosphatases involved in cellular regulation: purification and characterization of the glycogen-bound form of protein phosphatase-1 from rabbit skeletal muscle. Eur J Biochem 149:295-303, 1985.

405. Sutherland C, Campbell DG, Cohen P. Identification of insulin-stimulated protein kinase-1 as the rabbit equivalent of rsk-mo-2. Eur J Biochem 212:581-588, 1993.

406. Damsbo P, Vaag A, Hother-Nielsen O, Beck-Nielsen H. Reduced glycogen synthase activity in skeletal muscle from obese patients with and without type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 34:239-245, 1991.

407. Mandarino LJ, Wright KS, Verity LS, Nichols J, Bell JM, Kolterman OG, Beck-Nielsen H. Effects of insulin infusion on human skeletal muscle pyruvate dehydrogenase, phosphofructokinase, and glycogen synthase. Evidence for their role in oxidative glucose metabolism. J Clin Invest 80: 655-63, 1987.

408. Thorburn AW. Gumbiner B. Bulacan F, Wallace P, Henry RR. Intracellular glucose oxidation and glycogen synthase activity are reduced in non-insulin-dependent (type II) diabetes independent of impaired glucose uptake. J Clin Invest 85: 522-9, 1990.

409. Mandarino LJ, Consoli A, Jain A, Kelley DE. Interaction of carbohdyrate and fat fuels in human skeletal muscle: impact of obesity and NIDDM. Am J Physiol 270:E463-E470, 1996.

410. Nikoulina SE, Ciaraldi TP, Mudaliar S, Mohideen P, Carter L, Henry RR. Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. Diabetes 49:263-271, 2000.

411. Henry RR, Ciaraldi TP, Abrams-Carter L, Mudaliar S, Park KS, Nikoulina SE. Glycogen synthase activity is redued in cultured skeletal muscle cells of non-insulin-dependent diabetes mellitus subjects. J Clin Invest 98:1231-1236, 1996.

412. Wells AM, Sutcliffe IC, Johnson AB, Taylor R. Abnormal activation of glycogen synthesis in fibroblasts from NIDDM subjects. Evidence for an abnormality specific to glucose metabolism. Diabetes 42:583-589, 1993.

413. Nyomba BL, Freymond D, Raz I, Stone K, Mott DM, Bogardus C. Skeletal muscle glycogen synthase activity in subjects with non-insulin-dependent diabetes mellitus after glyburide therapy. Metabolism 39:1204-1210, 1990.

414. Pratipanawatr T, Cusi K, Ngo P, Pratipanawatr W, Mandarino LJ, DeFronzo RA. Normalization of plasma glucose concentration by insulin therapy improves insulin-stimulated glycogen synthesis in type 2 diabetes. Diabetes 51:462-468, 2002.

415. Vestergaard H, Lund S, Larsen FS, Bjerrum OJ, Pedersen O. Glycogen synthase and phosphofructokinase protein and mRNA levels in skeletal muscle from insulin-resistant patients with non-insulin-dependent diabetes mellitus. J Clin Invest 91:2342-2350, 1993.

416. Vestergaard H, Bjocbaek C, Andersen PH, Bak JF, Pedersen O. Impaired expression of glycogen synthase mRNA in skeletal muscle of NIDDM patients. Diabetes 40:1740-1745, 1991.

417. Browner MF, Nakano K, Bang AG, Fleffenzk RJ. Human muscle glycogen synthase with DNA sequence: anegatively charged protein with ansymmetric charge distribution. Proc Natl Acad Sci USA 86:1443-1447, 1989.

418. Majer M, Mott DM, Mochizuki H, Rowles JC, Pederson O, Knowler WC, Bogardus C, Prochazka M. Association of the glycogen synthase locus on 19q13 with NIDDM in Pima Indians. Diabetologia 39:314-321, 1996.

419. Orho M, Nikua-Ijas P, Schalin-Jantti C, Permutt MA, Groop LC. Isolatation and characterization of the human muscle glycogen synthase gene. Diabetes 44:1099-1105, 1995.

420. Bjorbaek C, Echward SM, Hubricht P, Vestergaard H, Hansen T, Zierath J, Pedersen O. Genetic variants in promoters and coding regions of the muscle glycogen synthase and the insulin-responsive GLUT4 genes in NIDDM. Diabetes 43:976-983, 1994.

421. Bjorbaek C, Fik TA, Echward SM, Yang P-Y, Vestergaard H, Wang JP, Webb GC, Richmond K, Hansen T, Erikson RL, Miklos GLG, Cohen PTW, Pedersen O. Cloning of human insulin-stimulated protein kinase (ISPK-1) gene and analysis of coding regiions and mRNA levels of the ISPK-1 and the protein phosphatase-1 genes in muscle from NIDDM patients. Diabetes 44:90-97, 1995.

422. Procharzka M, Michizuki H, Baier LJ, Cohen PTW, Bogardus C. Molecular and linkage analysis of type-1 protein phosphatase catalytic beta-subunit gene: lack of evidence for its mjaor role in insulin resistance in Pima Indians. Diabetologia 38:461-466, 1995.

423. Schalin-Jantti C, Harkonen M, Groop LC. Impaired activation of glycogen synthase in people at increased risk for developing NIDDM. Diabetes 41:598-604, 1992.

424. Falholt K, Jensen I, Lindkaer Jensen S, MortensenHB, Volund A, Heding LG,Norskov Petersen P, Falholt W. Carbohydrate and lipid metabolism of skeletal muscle in type 2 diabetic patients. Diab Med 5:27-31, 1988.

425. Mandarino LJ, Madar Z, Kolterman OG, Bell JM, Olefsky JM. Adipocyte glycogen synthase and pyruvate dehydrogenase in obese and type II diabetic patients. Am J Physiol 251:E489-E496, 1986.

426. Kelley D, Mokan M, Mandarino L. Intracellular defects in glucose metabolism in obese patients with noninsulin-dependent diabetes mellitus. Diabetes 41:698-706, 1992.


Google Gadget error

Comments (0)

You don't have permission to comment on this page.